



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, 15/62, C07K 14/47, 16/18, A61K 38/17, A01K 67/027, C12Q 1/68, G01N 33/68	A1	(11) International Publication Number: WO 98/54323 (43) International Publication Date: 3 December 1998 (03.12.98)
(21) International Application Number: PCT/US98/10862 (22) International Filing Date: 28 May 1998 (28.05.98) (30) Priority Data: 08/865,297 29 May 1997 (29.05.97) US (71) Applicant: DANA-FARBER CANCER INSTITUTE [US/US]; 44 Binney Street, Boston, MA 02115 (US). (72) Inventors: KANTETI, Prasad, V., S.; Apartment 503, 1575 Tremont Street, Boston, MA 02120 (US). AO, Zhaohui; Apartment E 144, 345 Avon Road, Devon, PA 19333 (US). SCHLOSSMAN, Stuart, F.; 1 Fox Place, Newton Centre, MA 02159 (US). (74) Agents: MANDRAGOURAS, Amy, E. et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: THE <i>SIVA</i> GENES INVOLVED IN CD27-MEDIATED APOPTOSIS (57) Abstract <p>The invention provides isolated nucleic acids molecules, designated <i>Siva</i> nucleic acid molecules, which encode proteins involved in immune cell apoptosis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing <i>Siva</i> nucleic acid molecules, host cells into which the expression vectors have been introduced, and non human transgenic animals in which a <i>Siva</i> gene has been introduced or disrupted. The invention still further provides isolated <i>Siva</i> proteins, fusion proteins, antigenic peptides and anti-<i>Siva</i> antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

THE SIVA GENES INVOLVED IN CD27-MEDIATED APOPTOSIS

Background of the Invention

5 CD27 is a member of the tumor necrosis factor receptor (TNFR) super family which also includes TNFR type I and II (CD120a and b), nerve growth factor receptor (NGFR), CD30 (associated with Hodgkin's lymphoma), Fas/Apo-1 (CD95), CD40, 4-1BB and OX40. These proteins are known to play a very important role in cell growth and differentiation as well as apoptosis or programmed cell death (Smith, C.A. et al.
10 (1994) *Cell* 76:959-962). Homology among these family members is restricted to the extracellular region and is characterized by the presence of a cysteine knot motif which occurs three times in CD27 (McDonald, N.Q. and Hendrickson, W.A. (1993) *Cell* 73:421-424).

CD27 is a glycosylated, type I transmembrane protein of about 55 kd and exists
15 as homodimers with a disulfide bridge linking the two monomers. The disulfide bridge is in the extracellular domain close to the membrane (Camerini, D. et al. (1991) *J. Immunol.* 147:3165-3169; Gravestien, L.A. et al. (1993) *Eur. J. Immunol.* 23:943-950). The ligand for CD27, CD70, belongs to the TNF family of ligands. CD70 is a type II transmembrane protein with an apparent molecular weight of 50 kd (Goodwin, R.G. et al.
20 al. (1993) *Cell* 73:447-456; Bowman, M.R. et al. (1994) *J. Immunol.* 152:1756-1761). Based on homology to TNF α and TNF β , especially in the β strands C, D, H and I, CD70 is predicted to have a trimeric structure made up of three identical subunits which possibly interact with three CD27 homodimers (Peitsch, M.C. and Tschopp, J. (1995) *Mol. Immunol.* 32:761-772). TNF α , which is also a type II transmembrane protein, is
25 released from the cell by proteolytic cleavage, whereas TNF β and NGF are secreted. So far there are no reports as to the existence of a naturally-occurring soluble form of CD70.

Expression of both CD27 and its ligand CD70 is restricted to discrete populations of both T and B cells. Although CD27 is expressed on the surface of resting
30 T cells, CD70 appears only on activated T and B cells (Sugita, K. et al. (1992) *J. Immunol.* 149:3208-3216; Hintzen, R.Q. et al. (1993) *J. Immunol.* 151:2426-2435; Agematsu, K. et al. (1994) *J. Immunol.* 153:1421-1429; Hintzen, R.Q. et al. (1995) *J. Immunol.* 154:2612-2623). Within the T cell subsets, CD27 is stably expressed on the CD45RA⁺ population of T cells even after activation, whereas on CD45RO⁺ cells, it is
35 weakly expressed and lost after activation (Sugita, K. et al. (1992) *J. Immunol.* 149:3208-3216; Hintzen, R.Q. et al. (1993) *J. Immunol.* 151:2426-2435). On CD45RA⁺ cells, activation by various means results in the up-regulation of CD27 expression

- 2 -

(Hintzen, R.Q. et al. (1993) *J. Immunol.* 151:2426-2435; Maurer, D. et al. (1990) *Eur. J. Immunol.* 20:2679-2684). Although CD70 is not detectable on either CD45RA⁺ or CD45RO⁺ resting T cells, activation through the TcR/CD3 complex results in the expression of CD70 predominantly on CD45RO⁺ T cells. The reciprocal expression of CD27 and CD70 on subsets of helper cells suggested an important role for the molecules in T-T interactions, T cell activation, and regulation of immunoglobulin synthesis. Significant amounts of CD27 can also be detected on a subpopulation of B cells present in peripheral blood and tonsils (Maurer, R.Q. et al. (1995) *J. Immunol.* 154:2612-2623), and the expression can be enhanced after activation with PMA/ionomycin. CD27 is also expressed on the CD3-bright thymocytes and can be induced in low CD3, CD4⁺, CD8⁺ (double positive) cells following activation with ConA and PMA/ionomycin (Martorell, J. et al. (1990) *J. Immunol.* 145:1356-1363). In contrast, in murine systems CD27 is constitutively expressed on all thymocytes (Gravestien, L.A. et al. (1994) *Int. J. Immunol.* 7:551-557). A soluble form of CD27 (the extracellular region clipped by a protease) appears in the culture supernatant and can also be detected in the serum of normal individuals (Hintzen, R.Q. et al. (1991) *J. Neuroimmunol.* 35:211-218). CD27 is also highly expressed in most of the B cell non-Hodgkin's lymphomas and B cell chronic lymphocytic leukemias (Ranheim, E.A. et al. (1995) *Blood* 85:3556-3565; Van Oers, M.H. et al. (1993) *Blood* 82:3430-3436). The B cell lines, Ramos and Raji, express significant levels of both CD27 and its ligand CD70.

Ligation of CD27 along with treatment of T cells with sub-optimal dose of PMA, PHA, anti-CD2 or anti-CD3 antibodies results in the proliferation of T cells, thus defining a costimulatory role for CD27. The CD27-mediated costimulatory effect can be specifically inhibited by the addition of anti-CD27 antibody, or recombinant sCD27 or anti-CD70 antibody (Sugita, K. et al. (1992) *J. Immunol.* 149:3208-3216; Hintzen, R.Q. et al. (1993) *J. Immunol.* 151:2426-2435; Hintzen, R.Q. et al. (1995) *J. Immunol.* 154:2612-2623, Kobata, T. et al. (1994) *J. Immunol.* 153:5422-5432). CD27/CD70 interaction can also result in the generation of cytolytic T cells (Goodwin, R.G. et al. (1993) *Cell* 73:447-456). Ligation of CD27 with CD70 on B cells significantly enhances IgG production, with a less pronounced effect on cell proliferation (Kobata, T. et al. (1995) *PNAS* 92:11249-11253). These studies clearly emphasize the importance of CD27/CD70 binding in both T-T, T-B and B-B cell interactions. Unlike CD28, CD27-mediated T cell proliferation does not support secretion of large amounts of IL2, clearly defining a different role for CD27/CD70 coupled co-stimulatory pathways. The CD45RA⁺ T cells which express CD27 are poor producers of IL2 and IL4 (Sugita, K. et al. (1992) *J. Immunol.* 151:2426-2435), as opposed to CD28 where coligation with TcR/CD3 complex results in elevated levels of IL2.

Summary of the Invention

This invention provides novel nucleic acid molecules which encode proteins, referred to herein as *Siva* proteins, which are capable of, for example, modulating apoptosis, e.g., apoptosis of immune cells. Nucleic acid molecules encoding the *Siva* proteins are referred to herein as *Siva* nucleic acid molecules. In a preferred embodiment, the *Siva* proteins interact with (e.g., bind to) CD27 or a portion thereof, e.g., the cytoplasmic tail of CD27, to modulate CD27-mediated immune cell apoptosis. As described herein, the *Siva* molecules (or modulators thereof) of the invention can be used to treat proliferative disorders, e.g., proliferative disorders of immune cells and autoimmune diseases, and to inhibit metastasis of tumor cells.

Accordingly, one aspect of the invention pertains to isolated nucleic acid molecules (e.g., cDNAs) comprising a nucleotide sequence encoding a *Siva* protein or portions thereof (e.g., biologically active or antigenic portions), as well as nucleic acid fragments suitable as primers or hybridization probes for the detection of *Siva*-encoding nucleic acid (e.g., mRNA). In particularly preferred embodiments, the isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3. In other particularly preferred embodiments, the isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes to or is at least about 75.5, 76, 77, 78, 79%, more preferably at least about 80%, even more preferably at least about 85%, still more preferably at least about 90%, and most preferably at least about 95% or more homologous to the nucleotide sequence shown in SEQ ID NO:1 or a portion thereof. In still other particularly preferred embodiments, the isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes to or is at least about 65%, preferably at least about 70%, more preferably at least about 75%, even more preferably at least about 80%, still more preferably at least about 85%, still more preferably at least about 90%, and most preferably at least about 95% or more homologous to the nucleotide sequence shown in SEQ ID NO:3 or a portion thereof. In other preferred embodiments, the isolated nucleic acid molecule encodes the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or a portion thereof. The preferred *Siva* proteins, e.g., *Siva-1* and *Siva-2*, of the present invention also preferably possess at least one of the *Siva* biological activities described herein.

In another embodiment, the isolated nucleic acid molecule encodes a protein or portion thereof wherein the protein or portion thereof includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 such that the protein or portion thereof maintains a *Siva* biological activity. Preferably, the protein or portion thereof encoded by the nucleic acid molecule

- 4 -

maintains the ability to modulate apoptosis, e.g., apoptosis of an immune cell. In one embodiment, the protein encoded by the nucleic acid molecule is at least about 71, 72, 73, 74, 75, 76, 77, 78, 79%, preferably at least about 80%, more preferably at least about 85%, even more preferably at least about 90%, and most preferably at least about 95% or more homologous to the amino acid sequence of SEQ ID NO:2 (e.g., the entire amino acid sequence of SEQ ID NO:2). In another preferred embodiment, the protein encoded by the nucleic acid molecule is at least about 65%, preferably at least about 70%, more preferably at least about 75%, even more preferably at least about 80%, still more preferably at least about 90%, and most preferably at least about 95% or more homologous to the amino acid sequence shown in SEQ ID NO:4 (e.g., the entire amino acid sequence of SEQ ID NO:4).

In yet another embodiment, the isolated nucleic acid molecule is derived from a human and encodes a portion of a protein which includes one or more of the following domains: a) a death domain homology region which is at least about 50% homologous to the amino acid sequence of SEQ ID NO:7 or SEQ ID NO:10; b) a zinc finger domain which is at least about 50% homologous to the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:11; and c) a B-Box like ring finger domain which is at least about 50% homologous to the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:12 and has one or more of the following biological activities: 1) it is capable of modulating apoptosis, e.g., apoptosis of an immune cell; 2) it can interact with (e.g., bind to) CD27 or a portion thereof, e.g., the cytoplasmic tail of CD27; and 3) it can modulate the activity of CD27.

In another embodiment, the isolated nucleic acid molecule is at least 15 nucleotides (e.g., at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, or more) in length and hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3. Preferably, the isolated nucleic acid molecule corresponds to a naturally-occurring nucleic acid molecule. More preferably, the isolated nucleic acid encodes naturally-occurring human *Siva-1* or human *Siva-2* or a biologically active portion thereof. Moreover, given the disclosure herein of *Siva*-encoding cDNA sequences (e.g., SEQ ID NO:1 and SEQ ID NO:3), antisense nucleic acid molecules (i.e., molecules which are complementary to the coding strand of the *Siva* cDNA sequences) are also provided by the invention.

Another aspect of the invention pertains to vectors, e.g., recombinant expression vectors, containing the nucleic acid molecules of the invention and host cells into which such vectors have been introduced. In one embodiment, such a host cell is used to produce *Siva* protein by culturing the host cell in a suitable medium. If desired, the *Siva* protein can be then isolated from the medium or the host cell.

- 5 -

Yet another aspect of the invention pertains to transgenic nonhuman animals in which a *Siva* gene has been introduced or altered. In one embodiment, the genome of the nonhuman animal has been altered by introduction of a nucleic acid molecule of the invention encoding *Siva* as a transgene. In another embodiment, an endogenous *Siva* gene within the genome of the nonhuman animal has been altered, e.g., functionally disrupted, by homologous recombination.

Still another aspect of the invention pertains to an isolated *Siva* protein, e.g., *Siva-1* and *Siva-2*, or a portion, e.g., a biologically active portion, thereof. In a preferred embodiment, the isolated *Siva* protein or portion thereof can modulate apoptosis, e.g., apoptosis of an immune cell. In another preferred embodiment, the isolated *Siva* protein or portion thereof is sufficiently homologous to an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 such that the protein or portion thereof maintains the ability to modulate apoptosis, e.g., apoptosis of an immune cell.

In one embodiment, the portion of the *Siva* protein includes a domain or motif, preferably a domain or motif which has a *Siva* biological activity. The domain can be a death domain homology region, a zinc finger domain, or a B-Box like ring finger domain. If the biologically active portion is derived from *Siva-1*, the death domain homology region is preferably at least about 50% homologous to the amino acid sequence of SEQ ID NO:7, the zinc finger domain is preferably at least about 50% homologous to the amino acid sequence of SEQ ID NO:8; and the B-Box like ring finger domain is preferably at least about 50% homologous to the amino acid sequence of SEQ ID NO:9. If the biologically active portion is derived from *Siva-2*, the death domain homology region is preferably at least about 50% homologous to the amino acid sequence of SEQ ID NO:10, the zinc finger domain is preferably at least about 50% homologous to the amino acid sequence of SEQ ID NO:11; and the B-Box like ring finger domain is preferably at least about 50% homologous to the amino acid sequence of SEQ ID NO:12. Preferably, the biologically active portion of the *Siva* protein which includes one or more of these domains also has one of the following biological activities: 1) it is capable of modulating apoptosis, e.g., apoptosis of an immune cell; 2) it can interact with (e.g., bind to) CD27 or a portion thereof, e.g., the cytoplasmic tail of CD27; and 3) it can modulate the activity of CD27.

The invention also provides an isolated preparation of a *Siva* protein. In preferred embodiments, the *Siva* protein comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4. In one preferred embodiment, the protein is at least about 71, 72, 73, 74, 75, 76, 77, 78, 79%, preferably at least about 80%, more preferably at least about 85%, even more preferably at least about 90%, and most preferably at least about 95% or more homologous to the amino acid sequence of SEQ ID NO:2 (e.g., the entire

- 6 -

amino acid sequence of SEQ ID NO:2). In another preferred embodiment, the protein is at least about 65%, preferably at least about 70%, more preferably at least about 80%, even more preferably at least about 85%, still more preferably at least about 90%, and most preferably at least about 95% or more homologous to the amino acid sequence shown in SEQ ID NO:4 (e.g., the entire amino acid sequence of SEQ ID NO:4).
5 Alternatively, the isolated *Siva* protein comprises an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, or is at least about 75.5, 76, 77, 78, 79%, more preferably at least about 80%, even more preferably at least about 85%, still more preferably at least about 90%, and
10 most preferably at least about 95% or more homologous to the nucleotide sequence shown in SEQ ID NO:1. In another embodiment, the isolated *Siva* protein comprises an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, or is at least about 65%, preferably at least about 70%, more preferably at least about 75%, even more preferably at least about 80%, still
15 more preferably at least about 85%, still more preferably at least about 90%, and most preferably at least about 95% or more homologous to the nucleotide sequence shown in SEQ ID NO:3. It is also preferred that the preferred forms of *Siva* possess one or more of the *Siva* biological activities described herein.

The *Siva* protein (or polypeptide) or a biologically active portion thereof can be
20 operatively linked to a non-*Siva* polypeptide to form a fusion protein. In addition, the *Siva* protein or a biologically active portion thereof can be incorporated into a pharmaceutical composition comprising the protein and a pharmaceutically acceptable carrier.

The *Siva* protein of the invention, or portions or fragments thereof, can be used
25 to prepare anti-*Siva* antibodies. Accordingly, the invention also provides an antigenic peptide of *Siva* which comprises at least 8 amino acid residues of the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:4 and encompasses an epitope of *Siva* such that an antibody raised against the peptide forms a specific immune complex with *Siva*. Preferably, the antigenic peptide comprises at least 10 amino acid residues, more
30 preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues. The invention further provides an antibody that specifically binds *Siva*. In one embodiment, the antibody is monoclonal. In another embodiment, the antibody is coupled to a detectable substance. In yet another embodiment, the antibody is incorporated into a pharmaceutical
35 composition comprising the antibody and a pharmaceutically acceptable carrier.

Another aspect of the invention pertains to methods for modulating a cell associated activity, e.g., proliferation, differentiation, survival. Such methods include

- 7 -

contacting the cell with an agent which modulates *Siva* protein activity or *Siva* nucleic acid expression such that a cell associated activity is altered relative to a cell associated activity (e.g., the same cell associated activity) of the cell in the absence of the agent. In a preferred embodiment, the cell is an immune cell (e.g., a T cell or a B cell). The agent which modulates *Siva* activity can be an agent which stimulates *Siva* protein activity or *Siva* nucleic acid expression. Examples of agents which stimulate *Siva* protein activity or *Siva* nucleic acid expression include small molecules such as small organic or inorganic molecules, active *Siva* proteins, and nucleic acids encoding *Siva* that have been introduced into the cell. Examples of agents which inhibit *Siva* protein activity or nucleic acid expression include small molecules, antisense *Siva* nucleic acid molecules, and antibodies that specifically bind to *Siva*.

The present invention also pertains to methods for treating subjects having various disorders. For example, the invention pertains to methods for treating a subject having a disorder characterized by aberrant *Siva* protein activity or nucleic acid expression such as a proliferative disorder (cancer), e.g., a proliferative disorder of an immune cell, or an autoimmune disease, e.g., multiple sclerosis. These methods include administering to the subject a *Siva* modulator (e.g., a small molecule, an antibody, a nucleic acid encoding a *Siva* protein or portion, a *Siva* protein or portion thereof) such that treatment of the subject occurs.

The invention also pertains to methods for detecting genetic lesions in a *Siva* gene, thereby determining if a subject with the lesioned gene is at risk for (or is predisposed to have) a disorder characterized by aberrant or abnormal *Siva* nucleic acid expression or *Siva* protein activity, e.g., a proliferative disorder or an autoimmune disease. The methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by an alteration affecting the integrity of a gene encoding a *Siva* protein, or the misexpression of a *Siva* gene.

Another aspect of the invention pertains to methods for detecting the presence of *Siva* in a biological sample. In a preferred embodiment, the methods involve contacting a biological sample (e.g., an immune cell, e.g., a peripheral blood lymphocyte) with a compound or an agent capable of detecting *Siva* protein or *Siva* mRNA such that the presence of *Siva* is detected in the biological sample. The compound or agent can be, for example, a labeled or labelable nucleic acid probe capable of hybridizing to *Siva* mRNA or a labeled or labelable antibody capable of binding to *Siva* protein.

The invention further provides methods for diagnosis of a subject with, for example, a proliferative disorder or an autoimmune disease, based on detection of *Siva* protein or mRNA. In one embodiment, the method involves contacting a cell or tissue sample (e.g., a peripheral blood lymphocyte sample) from the subject with an agent

- 8 -

capable of detecting *Siva* protein or mRNA, determining the amount of *Siva* protein or mRNA expressed in the cell or tissue sample, comparing the amount of *Siva* protein or mRNA expressed in the cell or tissue sample to a known standard or control sample and forming a diagnosis based on the amount of *Siva* protein or mRNA expressed in the cell
5 or tissue sample as compared to the standard or control sample. Preferably, the cell sample is an immune cell sample. Kits for detecting *Siva* in a biological sample are also within the scope of the invention.

Still another aspect of the invention pertains to methods, e.g., screening assays, for identifying a compound for treating a disorder characterized by aberrant *Siva* nucleic
10 acid expression or protein activity, e.g., a proliferative disorder or an autoimmune disease. These methods typically include assaying the ability of the compound or agent to modulate the expression of a *Siva* gene or the activity of a *Siva* protein. In a preferred embodiment, the method involves contacting a biological sample (e.g., a cell or tissue sample, e.g., an immune cell sample such as a peripheral blood lymphocyte sample)
15 obtained from a subject having the disorder with the compound or agent, comparing the amount of *Siva* protein expressed and/or measuring the activity of the *Siva* protein in the presence or absence of the compound or agent. An alteration in the amount of *Siva* nucleic acid expression or *Siva* protein activity in the cell exposed to the compound or agent in comparison to the unexposed sample is indicative of a modulation of *Siva*
20 nucleic acid expression and/or *Siva* protein activity.

The invention also pertains to methods for identifying a compound or agent which interacts with (e.g., binds to) a *Siva* protein. These methods can include the steps of contacting the *Siva* protein with the compound or agent under conditions which allow binding of the compound to the *Siva* protein to form a complex and detecting the
25 formation of a complex of the *Siva* protein and the compound in which the ability of the compound to bind to the *Siva* protein is indicated by the presence of the compound in the complex.

The invention further pertains to methods for identifying a compound or agent which modulates, e.g., stimulates or inhibits, the interaction of a *Siva* protein with a
30 target molecule, e.g., CD27 or a portion thereof, e.g., the cytoplasmic tail of CD27. In these methods, the *Siva* protein is contacted, in the presence of the compound or agent, with the target molecule under conditions which allow binding of the target molecule to the *Siva* protein to form a complex. An alteration, e.g., an increase or decrease, in complex formation between the *Siva* protein and the target molecule as compared to the
35 amount of complex formed in the absence of the compound or agent is indicative of the ability of the compound or agent to modulate the interaction of the *Siva* protein with a target molecule.

Brief Description of the Drawings

Figures 1a and 1b depict the nucleotide (SEQ ID NO:1) and deduced amino acid (SEQ ID NO:2) sequence of the human *Siva-1* gene including 5' and 3' untranslated regions.

Figures 2a and 2b depict the nucleotide (SEQ ID NO:5) and deduced amino acid (SEQ ID NO:6) sequence of the mouse *Siva* gene without the 5' and 3' untranslated regions.

Detailed Description of the Invention

The present invention is based on the discovery of novel molecules, referred to herein as *Siva* nucleic acid and protein molecules, which play a role in or function in programmed cell death or apoptosis. The *Siva* molecules, which are named after *Siva*, the Hindu god of destruction, were discovered based, at least in part, on experiments using the cytoplasmic tail of human CD27 as bait in a yeast two hybrid system to identify novel CD27-interacting proteins.

The human *Siva-1* nucleotide sequence (identified as described in Example I) and the predicted amino acid sequence of the human *Siva-1* protein are shown in Figure 1 and in SEQ ID NOs:1 and 2, respectively. The nucleotide sequence of *Siva-1* has been deposited with GenBank and assigned Accession Number U2938. The human *Siva-1* gene, which is approximately 885 nucleotides in length (the coding region is approximately 567 nucleotides in length), encodes a full length protein which is approximately 189 amino acid residues in length.

The *Siva-1* protein is rich in cysteines and contains several domains. These domains include

a) a death domain homology region (DDHR) which appears at amino acid residues 62 to 136 of SEQ ID NO:2 and which is also shown in the present application as a separate sequence designated SEQ ID NO:7. As used herein, a DDHR refers to a region of a *Siva* protein which includes at least about 40, preferably at least about 50, more preferably at least about 60, still more preferably at least about 70, and most preferably at least about 80 amino acid residues or more and which is at least about 10% or more homologous to the death domain of FADD (Chinnaiyan, A.M. et al. (1995) *Cell* 81:505-512), RIP (Stanger, B.Z. et al. (1995) *Cell* 81:513-523), TRADD (Hsu, H. et al. (1995) *Cell* 81:495-504), or Fas (Cleveland, J.L. and Ihle, J.N. (1995) *Cell* 81:479-482). The DDHR typically is a region of a protein which is involved in apoptosis. The DDHR can also be involved in, for example, modulation of transcription. In one embodiment, the DDHR of *Siva* is involved in activation of transcription factors such as NFkB. Methods for measuring NFkB activation are known in the art. Hsu, H. et al. (1995) *Cell* 81:495-504. In preferred embodiments, a *Siva* protein of the invention includes a

- 10 -

DDHR which is at least about 50%, more preferably at least about 60%, still more preferably at least about 70%, and most preferably at least about 80, 85, 90% or more homologous to the DDHR of *Siva-1* as shown in SEQ ID NO:7.;

5 b) a zinc finger domain at amino acid residues 164-184 of SEQ ID NO:2 and which is also shown in the present application as a separate sequence designated SEQ ID NO:8. As used herein, a zinc finger domain refers to a region of a *Siva* protein which comprises at least about 20 amino acid residues and which includes at least about 4, more preferably at least about 5 or more cysteine residues. The zinc finger domain is typically involved in binding of the *Siva* protein to another protein or to a nucleic acid.
10 For example, the zinc finger domain of *Siva* can be involved in modulating gene transcription in cells, e.g., immune cells. In preferred embodiments, a *Siva* protein of the invention includes a zinc finger domain which is at least about 50%, more preferably at least about 60%, still more preferably at least about 70%, and most preferably at least about 80, 85, 90% or more homologous to the zinc finger domain of *Siva-1* as shown in
15 SEQ ID NO:8; and

 c) and a B-box like ring finger domain at amino acid residues 128-159 of SEQ ID NO:2 and which is also shown in the present application as a separate sequence designated SEQ ID NO:9. This B-box like ring finger lacks histidine. As used herein, a B-box like ring finger domain refers to a region of a *Siva* protein which comprises at
20 least about 20, more preferably at least about 30 or more amino acid residues and which includes at least about 5, preferably at least about 6, more preferably at least about 7, and most preferably at least about 8 or more cysteine residues. The B-Box like ring finger domain can be involved in, for example, modulation of transcription. In one embodiment, the B-Box like ring finger domain of *Siva* is involved in activation of
25 transcription factors such as NFkB. In preferred embodiments, a *Siva* protein of the invention includes a B-Box like ring finger domain which is at least about 50%, more preferably at least about 60%, still more preferably at least about 70%, and most preferably at least about 80, 85, 90% or more homologous to the B-Box like ring finger domain of *Siva-1* as shown in SEQ ID NO:9.

30 Since the cysteine rich carboxy terminus of the *Siva-1* protein, which includes both the zinc finger domain and the B-box like ring finger domain, was present in the original yeast insert H2 used in the yeast two hybrid assays which led to the discovery of the *Siva* molecules, the cysteine rich carboxy terminus likely mediates binding to CD27, e.g., the CD27 cytoplasmic tail. Moreover, it is known that carboxy terminal zinc
35 fingers are involved in mediating protein-protein interactions (Freemont, P.S. (1993) *Ann. N.Y. Acad. Sci.* 684:174-192). Thus, as used herein, the language "CD27-binding

- 11 -

domain" refers to the combined zinc finger and B-box like ring finger domain of the *Siva* protein.

Using Northern analysis, the *Siva-1* protein was found to be expressed in spleen, thymus, prostate, testis, ovary, small intestine, colon, and peripheral blood lymphocytes as well as several cell lines including HeLa cells (ATCC Accession No. CCL 2: human cervical carcinoma cell line), Raji cells (ATCC Accession No. CCL 86: human Burkitt lymphoma cell line), HL60 cells (ATCC Accession No. CCL 240: human promyelocyte cell line), K562 cells (ATCC Accession No. CCL 243: human erythroleukemia cell line), MOTL-4 cells (ATCC Accession No. CRL 1582: human acute lymphoblastic leukemia cell line), SW480 cells (ATCC Accession No. CCL 228: human colorectal adenocarcinoma cell line), A549 cells (ATCC Accession No. CCL 185: human lung carcinoma cell line), and G-361 cells (ATCC Accession No. CRL 1424: human malignant melanoma cell line).

During a screen of a human thymus cDNA library using a partial clone of *Siva-1* to obtain the full length *Siva-1* nucleic acid molecule, a second *Siva* nucleic acid molecule, which appears to be an alternate splice form of *Siva-1*, was identified. The alternate splice form of *Siva-1* was named *Siva-2*. The *Siva-2* nucleic acid molecule is the same as that of *Siva-1* except that it includes a large in-frame deletion of nucleotides 157-351 of the nucleotide sequence shown in Figure 1 (nucleotides 289-483 of SEQ ID NO:1). The human *Siva-2* nucleotide sequence (identified as described in Example VI) and the predicted amino acid sequence of the human *Siva-2* protein are shown in SEQ ID NOs:3 and 4, respectively. The human *Siva-2* cDNA, which is approximately 690 nucleotides in length (the coding region is approximately 372 nucleotides in length), encodes a full length protein which is approximately 124 amino acid residues in length. The *Siva-2* protein is rich in cysteines and contains several domains including a portion of the death domain homology region (DDHR) of *Siva-1* at amino acid residues 54 to 118 of SEQ ID NO:4 and which is also shown in the present application as a separate sequence designated SEQ ID NO:10, a zinc finger domain at amino acid residues 99 to 119 of SEQ ID NO:4 and which is also shown in the present application as a separate sequence designated SEQ ID NO:11, and a B-box like ring finger domain at amino acid residues 63 to 94 of SEQ ID NO:4 and which is also shown in the present application as a separate sequence designated SEQ ID NO:12. The cysteine rich carboxy terminus of zinc finger domain and the B-box like ring finger domain together comprise a CD27-binding domain. As the *Siva-2* protein lacks most of the DDHR of the *Siva-1* protein, the *Siva-2* protein may be a naturally-occurring dominant negative regulatory form of *Siva-1* and thus may be able to inhibit the proapoptotic activity of *Siva-1*.

- 12 -

A mouse homologue of *Siva-1* was identified by sequencing the mouse cDNA insert of ATCC Accession No. 738252 and comparing it to the *Siva-1* nucleotide sequence. The nucleotide sequence of the mouse homologue (shown in SEQ ID NO:5) was found to be about 75% homologous to the nucleotide sequence of *Siva-1*. The amino acid sequence of the mouse homologue (shown in SEQ ID NO:6) was found to be about 70.3% homologous to the amino acid sequence of *Siva-1*.

The *Siva* proteins or biologically active portions thereof of the invention can have one or more of the following biological activities: 1) they can interact with (e.g., bind to) CD27, e.g., the cytoplasmic tail of CD27; 2) they can modulate the activity of CD27; and 3) they can modulate or regulate apoptosis, e.g., apoptosis of immune cells. Thus, in a preferred embodiment of the invention, the *Siva* molecules modulate CD27-mediated apoptosis of cells, e.g., immune cells. As used herein, the language "immune cell" refers to hematopoietic cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, dendritic cells, and other antigen presenting cells, natural killer (NK) cells, and lymphokine activated killer (LAK) cells. Thus, as elevated levels of soluble CD27 have been reported in cases of multiple sclerosis (Hinzten, R.Q. et al. (1991) *J. Neuroimmunol.* 35:211-218), and such elevated levels may inhibit the regulatory or other effects of CD70-expressing T and B cells, the *Siva* molecules (or modulators thereof) of the invention, which can modulate the activity of CD27, can be used to treat multiple sclerosis and other autoimmune diseases. It is also known that B cell cancers such as Non-Hodgkin's lymphoma and B cell chronic lymphocytic leukemia (B-CLL) do not undergo apoptosis despite the high expression of both CD27 and CD70. This is due to the fact that these cells release soluble CD27 which builds up in the body fluids and disrupts CD27-mediated apoptosis. Thus, the *Siva* molecules (or modulators thereof) of the invention can also be used to treat immune cell proliferative disorders such as Non-Hodgkin's lymphoma and leukemias. Moreover, disruption of binding between CD27 and CD70 by soluble CD27 aids in metastasis by, for example, loosening the homotypic cell-cell contact occurring through CD27 and CD70 interaction. By promoting apoptosis of the tumorigenic cells, the *Siva* molecules (or modulators thereof) of the invention can be used to inhibit tumor metastasis.

Various aspects of the invention are described in further detail in the following subsections:

I. Isolated Nucleic Acid Molecules

One aspect of the invention pertains to isolated nucleic acid molecules that encode *Siva* or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as primers or hybridization probes to identify *Siva*-encoding nucleic

- 13 -

acid (e.g., *Siva* mRNA). As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated *Siva* nucleic acid molecule can contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived (e.g., an immune cell). Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. For example, a human *Siva* cDNA can be isolated from a human thymus library using all or portion of SEQ ID NO:1 or SEQ ID NO:3 as a hybridization probe and standard hybridization techniques (e.g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). Moreover, a nucleic acid molecule encompassing all or a portion of SEQ ID NO:1 or SEQ ID NO:3 can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon the sequence of SEQ ID NO:1 or SEQ ID NO:3, respectively. For example, mRNA can be isolated from immune cells, e.g., peripheral blood lymphocytes (e.g., by the guanidinium-thiocyanate extraction procedure of Chirgwin et al. (1979) *Biochemistry* 18: 5294-5299) and cDNA can be prepared using reverse transcriptase (e.g., Moloney MLV reverse transcriptase, available from Gibco/BRL, Bethesda, MD; or AMV reverse transcriptase, available from Seikagaku America, Inc., St. Petersburg, FL). Synthetic oligonucleotide primers for PCR amplification can be designed based upon the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:3. A nucleic acid of the invention can be amplified using cDNA or, alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so

- 14 -

amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to a *Siva* nucleotide sequence can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

5 In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:3. The sequence of SEQ ID NO:1 corresponds to the human *Siva-1* cDNA. This cDNA comprises sequences encoding the *Siva-1* protein (i.e., "the coding region", from nucleotides 133 to 699), as well as 5' untranslated sequences (nucleotides 1 to 132) and
10 3' untranslated sequences (nucleotides 700 to 885). Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ ID NO:1 (e.g., nucleotides 133 to 699). The sequence of SEQ ID NO:3 corresponds to the human *Siva-2* cDNA. This cDNA comprises sequences encoding the *Siva-2* protein (i.e., "the coding region", from nucleotides 133 to 504), as well as 5' untranslated sequences (nucleotides 1 to 132) and
15 3' untranslated sequences (nucleotides 505 to 690). Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ ID NO:3 (e.g., nucleotides 133 to 504).

In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide
20 sequence shown in SEQ ID NO:1 or SEQ ID NO:3 or a portion of either of these nucleotide sequences. A nucleic acid molecule which is complementary to the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:3 is one which is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:3 such that it can hybridize to the nucleotide sequence shown in SEQ ID NO:1 or
25 SEQ ID NO:3, thereby forming a stable duplex.

In still another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which is at least about 75.5, 76, 77, 78, 79%, preferably at least about 80%, more preferably at least about 85%, even more preferably at least about 90%, and most preferably at least about 95% or more homologous to the
30 nucleotide sequence shown in SEQ ID NO:1 or a portion thereof. In still other particularly preferred embodiments, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which is at least about 65%, preferably at least about 70%, more preferably at least about 75%, even more preferably at least about 80%, still more preferably at least about 85%, yet more preferably at least about 90%, and most
35 preferably at least about 95% or more homologous to the nucleotide sequence shown in SEQ ID NO:3 or a portion thereof. In additional preferred embodiments, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which

- 15 -

hybridizes, e.g., hybridizes under stringent conditions, to the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, or a portion of either of these nucleotide sequences.

Moreover, the nucleic acid molecule of the invention can comprise only a portion of the coding region of SEQ ID NO:1 or SEQ ID NO:3, for example a fragment which
5 can be used as a probe or primer or a fragment encoding a biologically active portion of *Siva*. The nucleotide sequence determined from the cloning of the *Siva* gene from a mammal allows for the generation of probes and primers designed for use in identifying and/or cloning *Siva* homologues in other cell types, e.g. from other tissues, as well as *Siva* homologues from other mammals. The probe/primer typically comprises
10 substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 40, 50 or 75 consecutive nucleotides of SEQ ID NO:1 or SEQ ID NO:3 sense, an anti-sense sequence of SEQ ID NO:1 or SEQ ID NO:3, or naturally-occurring mutants thereof. Primers based on the nucleotide sequence
15 in SEQ ID NO:1 or SEQ ID NO:3 can be used in PCR reactions to clone *Siva* homologues. Probes based on the *Siva* nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In preferred embodiments, the probe further comprises a label group attached thereto, e.g. the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme
20 co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress a *Siva* protein, such as by measuring a level of a *Siva*-encoding nucleic acid in a sample of cells from a subject e.g., detecting *Siva* mRNA levels or determining whether a genomic *Siva* gene has been mutated or deleted.

In one embodiment, the nucleic acid molecule of the invention encodes a protein
25 or portion thereof which includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 such that the protein or portion thereof maintains the ability to modulate apoptosis, e.g., apoptosis of an immune cell. As used herein, the language "sufficiently homologous" refers to proteins or portions thereof which have amino acid sequences which include a minimum
30 number of identical or equivalent (e.g., an amino acid residue which has a similar side chain as an amino acid residue in SEQ ID NO:2 or SEQ ID NO:4) amino acid residues to an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 such that the protein or portion thereof has at least one *Siva* biological activity, e.g., is able to modulate apoptosis, e.g., apoptosis of an immune cell., e.g., CD27-mediated apoptosis of an
35 immune cell.

Portions of proteins encoded by the *Siva* nucleic acid molecule of the invention are preferably biologically active portions of the *Siva* protein. As used herein, the term

- 16 -

"biologically active portion of *Siva*" is intended to include a portion, e.g., a domain/motif, of *Siva* that has one or more of the following biological activities: 1) it can interact with (e.g., bind to) CD27, e.g., the cytoplasmic tail of CD27; 2) it can modulate the activity of CD27; and 3) it can modulate or regulate apoptosis, e.g., apoptosis of immune cells. In a preferred embodiment of the invention, the portion of the *Siva* protein is capable of modulating CD27-mediated apoptosis of cells, e.g., immune cells. Standard binding assays, e.g., immunoprecipitations and yeast two-hybrid assays as described herein, can be performed to determine the ability of a *Siva* protein or a biologically active portion thereof to interact with (e.g., bind to) CD27 or a portion thereof. To determine whether a *Siva* protein or a biologically active portion thereof can modulate the activity of CD27 and/or modulate apoptosis, immune cells which express CD27 can be transformed with nucleic acid encoding *Siva* such that *Siva* is overexpressed. Cell death can then be measured and compared to cell death in control cells. An increase in cell death in the cells which overexpress *Siva* as compared to the control cells is evidence that *Siva* modulates CD27 activity. An example of such a test is described in Example V.

In one embodiment, the biologically active portion of *Siva* comprises a domain or motif, e.g., a domain or motif which has a *Siva* biological activity described herein. The domain or motif can be a death domain homology region, a zinc finger domain, or a B-Box like ring finger domain or a combination thereof, e.g., a CD27-binding domain. If the biologically active portion is derived from *Siva-1*, the death domain homology region is preferably at least about 50%, more preferably at least about 60%, still more preferably at least about 70%, yet more preferably at least about 80%, and most preferably at least about 90% or more homologous to the amino acid sequence of SEQ ID NO:7, the zinc finger domain is preferably at least about 50%, more preferably at least about 60%, still more preferably at least about 70%, yet more preferably at least about 80%, and most preferably at least about 90% or more homologous to the amino acid sequence of SEQ ID NO:8; and the B-Box like ring finger domain is preferably at least about 50%, more preferably at least about 60%, still more preferably at least about 70%, yet more preferably at least about 80%, and most preferably at least about 90% or more homologous to the amino acid sequence of SEQ ID NO:9. In a preferred embodiment, the biologically active portion comprises the death domain homology region of *Siva-1* as shown in SEQ ID NO:7. In another preferred embodiment, the biologically active portion comprises the zinc finger domain of *Siva-1* as shown in SEQ ID NO:8. In yet another preferred embodiment, the biologically active portion comprises the B-Box like ring finger domain of *Siva-1* as shown in SEQ ID NO:9.

- 17 -

If the biologically active portion is derived from *Siva-2*, the death domain homology region is preferably at least about 50%, more preferably at least about 60%, still more preferably at least about 70%, yet more preferably at least about 80%, and most preferably at least about 90% or more homologous to the amino acid sequence of SEQ ID NO:10, the zinc finger domain is preferably at least about 50%, more preferably at least about 60%, still more preferably at least about 70%, yet more preferably at least about 80%, and most preferably at least about 90% or more homologous to the amino acid sequence of SEQ ID NO:11; and the B-Box like ring finger domain is preferably at least about 50%, more preferably at least about 60%, still more preferably at least about 70%, yet more preferably at least about 80%, and most preferably at least about 90% or more homologous to the amino acid sequence of SEQ ID NO:12. In a preferred embodiment, the biologically active portion comprises the death domain homology region of *Siva-2* as shown in SEQ ID NO:10. In another preferred embodiment, the biologically active portion comprises the zinc finger domain of *Siva-2* as shown in SEQ ID NO:11. In yet another preferred embodiment, the biologically active portion comprises the B-Box like ring finger domain of *Siva-2* as shown in SEQ ID NO:12. Additional nucleic acid fragments encoding biologically active portions of *Siva* can be prepared by isolating a portion of SEQ ID NO:1 or SEQ ID NO:3, expressing the encoded portion of *Siva* protein or peptide (e.g., by recombinant expression *in vitro*) and assessing the activity of the encoded portion of *Siva* protein or peptide.

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:3 (and portions thereof) due to degeneracy of the genetic code and thus encode the same *Siva* protein as that encoded by the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:3. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:4.

In addition to the human *Siva* nucleotide sequences shown in SEQ ID NO:1 and SEQ ID NO:3, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of *Siva* may exist within a population (e.g., the human population). Such genetic polymorphism in the *Siva* gene may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a *Siva* protein, preferably a mammalian *Siva* protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the *Siva* gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in *Siva* that are the result of natural

- 18 -

allelic variation and that do not alter the functional activity of *Siva* are intended to be within the scope of the invention. Moreover, nucleic acid molecules encoding *Siva* proteins from other species, and thus which have a nucleotide sequence which differs from the human sequence of SEQ ID NO:1 or SEQ ID NO:3, are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and nonhuman homologues of the human *Siva* cDNA of the invention can be isolated based on their homology to the human *Siva* nucleic acid disclosed herein using the human cDNA, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3. In other embodiments, the nucleic acid is at least 30, 50, 100, 250 or 500 nucleotides in length. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.

Preferably, the conditions are such that sequences at least about 65%, more preferably at least about 70%, and even more preferably at least about 75% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO:1 or SEQ ID NO:3 corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein). In one embodiment, the nucleic acid encodes a natural human *Siva*.

In addition to naturally-occurring allelic variants of the *Siva* sequence that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3, thereby leading to changes in the amino acid sequence of the encoded *Siva* protein, without altering the functional ability of the *Siva* protein. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID NO:1 or SEQ ID NO:3. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of *Siva*

- 19 -

(e.g., the sequence of SEQ ID NO:2 or SEQ ID NO:4) without altering the activity of *Siva*, whereas an "essential" amino acid residue is required for *Siva* activity. For example, conserved amino acid residues, e.g., cysteines, in the B-Box like ring finger domain and zinc finger domain of *Siva* are most likely important for binding to CD27 proteins and thus may be essential residues of *Siva*. Other amino acid residues, however, (e.g., those that are not conserved or only semi-conserved in the domains of *Siva* described herein) may not be essential for activity and thus are likely to be amenable to alteration without altering *Siva* activity.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding *Siva* proteins that contain changes in amino acid residues that are not essential for *Siva* activity. Such *Siva* proteins differ in amino acid sequence from SEQ ID NO:2 or SEQ ID NO:4 yet retain at least one of the *Siva* activities described herein. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a *Siva-1* protein, wherein the *Siva-1* protein comprises an amino acid sequence at least about 71, 72, 73, 74, 75, 76, 77, 78, 79%, preferably at least about 80%, more preferably at least about 85%, and even more preferably at least about 90%, and most preferably at least about 95% or more homologous to the amino acid sequence of SEQ ID NO:2 (e.g., the entire amino acid sequence of SEQ ID NO:2) and is capable of modulating apoptosis, e.g., apoptosis of an immune cell. In another embodiment, the nucleic acid molecule comprises a nucleotide sequence encoding a *Siva-2* protein, wherein the *Siva-2* protein comprises an amino acid sequence which is at least about 65%, preferably at least about 70%, more preferably at least about 75%, even more preferably at least about 80%, still more preferably at least about 90%, and most preferably at least about 95% or more homologous to the nucleotide sequence shown in SEQ ID NO:4 (e.g., the entire amino acid sequence of SEQ ID NO:4) and is capable of modulating apoptosis, e.g., apoptosis of an immune cell.

To determine the percent homology of two amino acid sequences (e.g., SEQ ID NO:2 and a mutant form thereof or SEQ ID NO:4 or a mutant form thereof) or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of one protein or nucleic acid for optimal alignment with the other protein or nucleic acid). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in one sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the other sequence (e.g., a mutant form of *Siva*), then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity"). The percent homology between the two sequences is a function of the number of identical positions

- 20 -

shared by the sequences (i.e., % homology = # of identical positions/total # of positions x 100).

An isolated nucleic acid molecule encoding a *Siva* protein homologous to the protein of SEQ ID NO:2 or SEQ ID NO:4 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3, respectively, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into SEQ ID NO:1 or SEQ ID NO:3 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in *Siva* is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a *Siva* coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for a *Siva* activity described herein to identify mutants that retain *Siva* activity. Following mutagenesis of SEQ ID NO:1 or SEQ ID NO:3, the encoded protein can be expressed recombinantly (e.g., as described in Example IV) and the activity of the protein can be determined using, for example, assays described herein.

In addition to the nucleic acid molecules encoding *Siva* proteins described above, another aspect of the invention pertains to isolated nucleic acid molecules which are antisense thereto. An "antisense" nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire *Siva* coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding *Siva*. The term "coding region" refers to the region of the nucleotide sequence

- 21 -

comprising codons which are translated into amino acid residues (e.g., the entire coding region of SEQ ID NO:1 comprises nucleotides 133 to 699, the entire coding region of SEQ ID NO:3 comprises nucleotides 133 to 504). In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding *Siva*. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding *Siva* disclosed herein (e.g., SEQ ID NO:1, SEQ ID NO:3), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of *Siva* mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of *Siva* mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of *Siva* mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA

- 22 -

transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an *Siva* protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of an antisense nucleic acid molecule of the invention includes direct injection at a tissue site. Alternatively, an antisense nucleic acid molecule can be modified to target selected cells and then administered systemically. For example, for systemic administration, an antisense molecule can be modified such that it specifically binds to a receptor or an antigen expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecule to a peptide or an antibody which binds to a cell surface receptor or antigen. The antisense nucleic acid molecule can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gaultier et al. (1987) *Nucleic Acids Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-O-methylribonucleotide (Inoue et al. (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) *FEBS Lett.* 215:327-330).

In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) *Nature* 334:585-591)) can be used to catalytically cleave *Siva* mRNA transcripts to thereby inhibit translation of *Siva* mRNA. A ribozyme having specificity for a *Siva*-encoding nucleic acid can be designed based upon the nucleotide sequence of a *Siva* cDNA disclosed herein (i.e., SEQ ID NO:1 and SEQ ID NO:3). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a *Siva*-encoding mRNA. See, e.g., Cech et al. U.S.

- 23 -

Patent No. 4,987,071 and Cech et al. U.S. Patent No. 5,116,742. Alternatively, *Siva* mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel, D. and Szostak, J.W. (1993) *Science* 261:1411-1418.

5 Alternatively, *Siva* gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the *Siva* (e.g., the *Siva* promoter and/or enhancers) to form triple helical structures that prevent transcription of the *Siva* gene in target cells. See generally, Helene, C. (1991) *Anticancer Drug Des.* 6(6):569-84; Helene, C. et al. (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher, L.J. (1992)
10 *Bioassays* 14(12):807-15.

II. Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding *Siva* (or a portion thereof). As used herein,
15 the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication
20 in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they
25 are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral
30 vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory
35 sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of

- 24 -

interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., *Siva* proteins, mutant forms of *Siva*, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of *Siva* in prokaryotic or eukaryotic cells. For example, *Siva* can be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST),

- 25 -

maltose E binding protein, or protein A, respectively, to the target recombinant protein. In one embodiment, the coding sequence of the *Siva* is cloned into a pGEX expression vector to create a vector encoding a fusion protein comprising, from the N-terminus to the C-terminus, GST-thrombin cleavage site-*Siva*. The fusion protein can be purified by affinity chromatography using glutathione-agarose resin. Recombinant *Siva* unfused to GST can be recovered by cleavage of the fusion protein with thrombin.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann et al., (1988) *Gene* 69:301-315) and pET 11d (Studier et al., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 60-89). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident λ prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada et al. (1992) *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the *Siva* expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari, et al., (1987) *Embo J.* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz et al., (1987) *Gene* 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, CA).

Alternatively, *Siva* can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al. (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) *Nature* 329:840) and pMT2PC

- 26 -

(Kaufman et al. (1987) *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.*

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al. (1987) *Genes Dev.* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji et al. (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) *PNAS* 86:5473-5477), pancreas-specific promoters (Edlund et al. (1985) *Science* 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the α -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to *Siva* mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene

- 27 -

expression using antisense genes see Weintraub, H. et al., Antisense RNA as a molecular tool for genetic analysis, *Reviews - Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, *Siva* protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (*Molecular Cloning: A Laboratory Manual*, 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding *Siva* or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) *Siva* protein. Accordingly, the invention further provides methods for producing *Siva* protein using the host cells of the invention.

- 28 -

In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding *Siva* has been introduced) in a suitable medium until *Siva* is produced. In another embodiment, the method further comprises isolating *Siva* from the medium or the host cell.

5 The host cells of the invention can also be used to produce nonhuman transgenic animals. The nonhuman transgenic animals can be used in screening assays designed to identify agents or compounds, e.g., drugs, pharmaceuticals, etc., which are capable of ameliorating detrimental symptoms of selected disorders such as proliferative disorders and autoimmune diseases. For example, in one embodiment, a host cell of the invention
10 is a fertilized oocyte or an embryonic stem cell into which *Siva*-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous *Siva* sequences have been introduced into their genome or homologous recombinant animals in which endogenous *Siva* sequences have been altered. Such animals are useful for studying the function and/or activity of *Siva* and for
15 identifying and/or evaluating modulators of *Siva* activity. As used herein, a "transgenic animal" is a nonhuman animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include nonhuman primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA which is integrated into the
20 genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a nonhuman animal, preferably a mammal, more preferably a mouse, in which an endogenous *Siva* gene has been altered by homologous
25 recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing *Siva*-encoding nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by
30 microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The human *Siva* cDNA sequence of SEQ ID NO:1 or SEQ ID NO:3 can be introduced as a transgene into the genome of a nonhuman animal. Alternatively, a nonhuman homologue of the human *Siva* gene can be isolated based on hybridization to the human *Siva* cDNA (described further in subsection I
35 above) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the *Siva* transgene to

- 29 -

direct expression of *Siva* protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Patent No. 4,873,191 by Wagner et al. and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the *Siva* transgene in its genome and/or expression of *Siva* mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding *Siva* can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a *Siva* gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the *Siva* gene. The *Siva* gene can be a human gene (e.g., from a human genomic clone isolated from a human genomic library screened with the cDNA of SEQ ID NO:1 or SEQ ID NO:3), but more preferably, is a nonhuman homologue of a human *Siva* gene. For example, a nonhuman homologue of the human *Siva* gene can be isolated from a relevant genomic DNA library using the human *Siva* cDNA of SEQ ID NO:1 or SEQ ID NO:3 as a probe. The nonhuman homologue *Siva* gene then can be used to construct a homologous recombination vector suitable for altering an endogenous *Siva* gene in the genome of nonhuman animal from which the *Siva* gene is derived. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous *Siva* gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous *Siva* gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous *Siva* protein). In the homologous recombination vector, the altered portion of the *Siva* gene is flanked at its 5' and 3' ends by additional nucleic acid of the *Siva* gene to allow for homologous recombination to occur between the exogenous *Siva* gene carried by the vector and an endogenous *Siva* gene in an embryonic stem cell. The additional flanking *Siva* nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (see e.g., Thomas, K.R. and Capecchi, M. R. (1987) *Cell* 51:503 for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced *Siva*

- 30 -

gene has homologously recombined with the endogenous *Siva* gene are selected (see e.g., Li, E. et al. (1992) *Cell* 69:915). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see e.g., Bradley, A. in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E.J.

- 5 Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing
10 homologous recombination vectors and homologous recombinant animals are described further in Bradley, A. (1991) *Current Opinion in Biotechnology* 2:823-829 and in PCT International Publication Nos.: WO 90/11354 by Le Mouellec et al.; WO 91/01140 by Smithies et al.; WO 92/0968 by Zijlstra et al.; and WO 93/04169 by Berns et al.

- 15 In another embodiment, transgenic nonhumans animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, see, e.g., Lakso et al. (1992) *PNAS* 89:6232-6236. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman et al. (1991) *Science* 251:1351-1355. If
20 a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

- 25 Clones of the nonhuman transgenic animals described herein can also be produced according to the methods described in Wilmut, I. et al. (1997) *Nature* 385:810-813 and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, e.g., through
30 the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

- 31 -

III. Isolated *Siva* Proteins and Anti-*Siva* Antibodies

Another aspect of the invention pertains to isolated *Siva* proteins, and biologically active portions thereof, as well as peptide fragments suitable for use as immunogens to raise anti-*Siva* antibodies. An "isolated" or "purified" protein or
5 biologically active portion thereof is substantially free of cellular material when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of *Siva* protein in which the protein is separated from cellular components of the cells in which it is naturally or recombinantly produced. In one
10 embodiment, the language "substantially free of cellular material" includes preparations of *Siva* protein having less than about 30% (by dry weight) of non-*Siva* protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-*Siva* protein, still more preferably less than about 10% of non-*Siva* protein, and most preferably less than about 5% non-*Siva* protein. When the *Siva* protein or
15 biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation. The language "substantially free of chemical precursors or other chemicals" includes preparations of *Siva* protein in which the protein
20 is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of *Siva* protein having less than about 30% (by dry weight) of chemical precursors or non-*Siva* chemicals, more preferably less than about 20% chemical precursors or non-*Siva* chemicals, still more
25 preferably less than about 10% chemical precursors or non-*Siva* chemicals, and most preferably less than about 5% chemical precursors or non-*Siva* chemicals. In preferred embodiments, isolated proteins or biologically active portions thereof lack contaminating proteins from the same animal from which the *Siva* protein is derived. Typically, such proteins are produced by recombinant expression of, for example, a
30 human *Siva* protein in a nonhuman cell.

An isolated *Siva* protein or a portion thereof of the invention can modulate apoptosis, e.g., apoptosis of an immune cell. In preferred embodiments, the protein or portion thereof comprises an amino acid sequence which is sufficiently homologous to an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 such that the protein or
35 portion thereof maintains the ability to modulate apoptosis, e.g., apoptosis of an immune cell. The portion of the protein is preferably a biologically active portion as described herein. In another preferred embodiment, the *Siva* protein (i.e., amino acid residues 1-

- 32 -

189 of the *Siva-1* protein) has an amino acid sequence shown in SEQ ID NO:2. In yet another preferred embodiment, the *Siva* protein (i.e., amino acid residues 1 to 124 of the *Siva-2* protein) has an amino acid sequence shown in SEQ ID NO:4. In yet another preferred embodiment, the *Siva* protein has an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3. In still another preferred embodiment, the *Siva* protein has an amino acid sequence which is encoded by a nucleotide sequence which is at least about 75.5, 76, 77, 78, 79%, preferably at least about 80%, more preferably at least about 85%, still more preferably at least about 90%, and most preferably at least about 95% or more homologous to the nucleotide sequence shown in SEQ ID NO:1. In still another particularly preferred embodiments, the *Siva* protein has an amino acid sequence which is encoded by a nucleotide sequence which is at least about 65%, preferably at least about 70%, more preferably at least about 75%, even more preferably at least about 80%, still more preferably at least about 85%, yet more preferably at least about 90%, and most preferably at least about 95% or more homologous to the nucleotide sequence shown in SEQ ID NO:3. The preferred *Siva* proteins of the present invention also preferably possess at least one of the *Siva* biological activities described herein.

In other embodiments, the *Siva* protein is substantially homologous to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 and retains the functional activity of the protein of SEQ ID NO:2 or SEQ ID NO:4 yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail in subsection I above.

Biologically active portions of the *Siva* protein include peptides comprising amino acid sequences derived from the amino acid sequence of the *Siva* protein, e.g., the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:4 or the amino acid sequence of a protein homologous to the *Siva* protein, which include less amino acids than the full length *Siva* protein or the full length protein which is homologous to the *Siva* protein, and exhibit at least one biological activity of the *Siva* protein. Typically, biologically active portions (peptides, e.g., peptides which are, for example, 5, 10, 15, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids in length) comprise a domain or motif, e.g., a death domain homology region, a zinc finger domain, or a B-Box like ring finger domain, with at least one activity of the *Siva* protein. In a preferred embodiment, the death domain homology region comprises the amino acid sequence of SEQ ID NO:7 or SEQ ID NO:9. In another preferred embodiment, the zinc finger domain comprises the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:11. In yet another preferred embodiment, the B-Box like ring finger domain comprises the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:12. Preferably, the preferred biologically

- 33 -

active portions of the *Siva* proteins have one or more of the following biological activities: 1) it is capable of modulating apoptosis, e.g., apoptosis of an immune cells; 2) it can interact with (e.g., bind to) CD27 or a portion thereof, e.g., the cytoplasmic tail of CD27; and 3) it can modulate the activity of CD27. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the biological activities described herein. Preferably, the biologically active portions of the *Siva* protein include one or more selected domains/motifs or portions thereof having biological activity.

Siva proteins are preferably produced by recombinant DNA techniques. For example, a nucleic acid molecule encoding the protein is cloned into an expression vector (as described above), the expression vector is introduced into a host cell (as described above) and the *Siva* protein is expressed in the host cell. The *Siva* protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Alternative to recombinant expression, a *Siva* protein, polypeptide, or peptide can be synthesized chemically using standard peptide synthesis techniques. Moreover, native *Siva* protein can be isolated from cells (e.g., peripheral blood lymphocytes), for example using an anti-*Siva* antibody (described further below).

The invention also provides *Siva* chimeric or fusion proteins. As used herein, an *Siva* "chimeric protein" or "fusion protein" comprises a *Siva* polypeptide operatively linked to a non-*Siva* polypeptide. A "*Siva* polypeptide" refers to a polypeptide having an amino acid sequence corresponding to *Siva*, whereas a "non-*Siva* polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the *Siva* protein, e.g., a protein which is different from the *Siva* protein and which is derived from the same or a different organism. Within the fusion protein, the term "operatively linked" is intended to indicate that the *Siva* polypeptide and the non-*Siva* polypeptide are fused in-frame to each other. The non-*Siva* polypeptide can be fused to the N-terminus or C-terminus of the *Siva* polypeptide. For example, in one embodiment the fusion protein is a GST-*Siva* fusion protein in which the *Siva* sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant *Siva*. In another embodiment, the fusion protein is a *Siva* protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of *Siva* can be increased through use of a heterologous signal sequence.

Preferably, a *Siva* chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended

- 34 -

termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers.

5 Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel et al. John Wiley & Sons: 1992). Moreover, many expression vectors are commercially
10 available that already encode a fusion moiety (e.g., a GST polypeptide). A *Siva*-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the *Siva* protein.

The present invention also pertains to homologues of the *Siva* proteins which function as either a *Siva* agonist (mimetic) or a *Siva* antagonist. In a preferred
15 embodiment, the *Siva* agonists and antagonists stimulate or inhibit, respectively, a subset of the biological activities of the naturally-occurring form of the *Siva* protein. Thus, specific biological effects can be elicited by treatment with a homologue of limited function. In one embodiment, treatment of a subject with a homologue having a subset of the biological activities of the naturally-occurring form of the protein has fewer side
20 effects in a subject relative to treatment with the naturally-occurring form of the *Siva* protein.

Homologues of the *Siva* protein can be generated by mutagenesis, e.g., discrete point mutation or truncation of the *Siva* protein. As used herein, the term "homologue" refers to a variant form of the *Siva* protein which acts as an agonist or antagonist of the
25 activity of the *Siva* protein. An agonist of the *Siva* protein can retain substantially the same, or a subset, of the biological activities of the *Siva* protein. An antagonist of the *Siva* protein can inhibit one or more of the activities of the naturally-occurring form of the *Siva* protein, by, for example, competitively binding to a downstream or upstream member of the *Siva* cascade which includes the *Siva* protein. Thus, the mammalian *Siva*
30 protein and homologues thereof of the present invention can be either positive or negative regulators of apoptosis, e.g., apoptosis of an immune cell.

In an alternative embodiment, homologues of the *Siva* protein can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the *Siva* protein for *Siva* protein agonist or antagonist activity. In one embodiment, a variegated
35 library of *Siva* variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of *Siva* variants can be produced by, for example, enzymatically ligating a mixture of synthetic

- 35 -

oligonucleotides into gene sequences such that a degenerate set of potential *Siva* sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of *Siva* sequences therein.

There are a variety of methods which can be used to produce libraries of potential *Siva*

5 homologues from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential *Siva* sequences. Methods for synthesizing degenerate
10 oligonucleotides are known in the art (see, e.g., Narang, S.A. (1983) *Tetrahedron* 39:3; Itakura et al. (1984) *Annu. Rev. Biochem.* 53:323; Itakura et al. (1984) *Science* 198:1056; Ike et al. (1983) *Nucleic Acid Res.* 11:477.

In addition, libraries of fragments of the *Siva* coding region can be used to generate a variegated population of *Siva* fragments for screening and subsequent

15 selection of homologues of an *Siva* protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an *Siva* coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different
20 nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the *Siva* protein.

Several techniques are known in the art for screening gene products of

25 combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of *Siva* homologues. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into
30 replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the
35 screening assays to identify *Siva* homologues (Arkin and Yourvan (1992) *PNAS* 89:7811-7815; Delgrave et al. (1993) *Protein Engineering* 6(3):327-331).

- 36 -

An isolated *Siva* protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind *Siva* using standard techniques for polyclonal and monoclonal antibody preparation. The full-length *Siva* protein can be used or, alternatively, the invention provides antigenic peptide fragments of *Siva* for use as immunogens. The antigenic peptide of *Siva* comprises at least 8 amino acid residues of the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:4 and encompasses an epitope of *Siva* such that an antibody raised against the peptide forms a specific immune complex with *Siva*. Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues. An example of an antigenic *Siva* peptide is the peptide which includes amino acid residues 40 to 73 of SEQ ID NO:2. This peptide was coupled to KLH and used to raise polyclonal anti-*Siva* antibodies in mice. Other preferred epitopes encompassed by the antigenic peptide are regions of *Siva* that are located on the surface of the protein, e.g., hydrophilic regions.

A *Siva* immunogen typically is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, recombinantly expressed *Siva* protein or a chemically synthesized *Siva* peptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic *Siva* preparation induces a polyclonal anti-*Siva* antibody response.

Accordingly, another aspect of the invention pertains to anti-*Siva* antibodies. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as *Siva*. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that bind *Siva*. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of *Siva*. A monoclonal antibody composition thus typically displays a single binding affinity for a particular *Siva* protein with which it immunoreacts.

Polyclonal anti-*Siva* antibodies can be prepared as described above by immunizing a suitable subject with a *Siva* immunogen. The anti-*Siva* antibody titer in the immunized subject can be monitored over time by standard techniques, such as with

- 37 -

an enzyme linked immunosorbent assay (ELISA) using immobilized *Siva*. If desired, the antibody molecules directed against *Siva* can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, e.g., when the anti-*Siva* antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) *Nature* 256:495-497) (see also, Brown et al. (1981) *J. Immunol.* 127:539-46; Brown et al. (1980) *J. Biol. Chem.* 255:4980-83; Yeh et al. (1976) *PNAS* 76:2927-31; and Yeh et al. (1982) *Int. J. Cancer* 29:269-75), the more recent human B cell hybridoma technique (Kozbor et al. (1983) *Immunol Today* 4:72), the EBV-hybridoma technique (Cole et al. (1985), *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing monoclonal antibody hybridomas is well known (see generally R. H. Kenneth, in *Monoclonal Antibodies: A New Dimension In Biological Analyses*, Plenum Publishing Corp., New York, New York (1980); E. A. Lerner (1981) *Yale J. Biol. Med.*, 54:387-402; M. L. Gefter et al. (1977) *Somatic Cell Genet.* 3:231-36). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with a *Siva* immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds *Siva*.

Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-*Siva* monoclonal antibody (see, e.g., G. Galfre et al. (1977) *Nature* 266:55052; Gefter et al. *Somatic Cell Genet.*, cited *supra*; Lerner, *Yale J. Biol. Med.*, cited *supra*; Kenneth, *Monoclonal Antibodies*, cited *supra*). Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods which also would be useful. Typically, the immortal cell line (e.g., a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line. Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium"). Any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, e.g., the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Ag14 myeloma lines. These myeloma lines are available from ATCC. Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol ("PEG"). Hybridoma

- 38 -

cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind *Siva*, e.g., using a standard ELISA assay.

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-*Siva* antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with *Siva* to thereby isolate immunoglobulin library members that bind *Siva*. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SurfZAP™ Phage Display Kit*, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, Ladner et al. U.S. Patent No. 5,223,409; Kang et al. PCT International Publication No. WO 92/18619; Dower et al. PCT International Publication No. WO 91/17271; Winter et al. PCT International Publication WO 92/20791; Markland et al. PCT International Publication No. WO 92/15679; Breitling et al. PCT International Publication WO 93/01288; McCafferty et al. PCT International Publication No. WO 92/01047; Garrard et al. PCT International Publication No. WO 92/09690; Ladner et al. PCT International Publication No. WO 90/02809; Fuchs et al. (1991) *Bio/Technology* 9:1370-1372; Hay et al. (1992) *Hum. Antibod. Hybridomas* 3:81-85; Huse et al. (1989) *Science* 246:1275-1281; Griffiths et al. (1993) *EMBO J* 12:725-734; Hawkins et al. (1992) *J. Mol. Biol.* 226:889-896; Clarkson et al. (1991) *Nature* 352:624-628; Gram et al. (1992) *PNAS* 89:3576-3580; Garrad et al. (1991) *Bio/Technology* 9:1373-1377; Hoogenboom et al. (1991) *Nuc. Acid Res.* 19:4133-4137; Barbas et al. (1991) *PNAS* 88:7978-7982; and McCafferty et al. *Nature* (1990) 348:552-554.

Additionally, recombinant anti-*Siva* antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in Robinson et al. International Application No. PCT/US86/02269; Akira, et al. European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al. European Patent Application 173,494; Neuberger et al. PCT International Publication No. WO 86/01533; Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al. European Patent Application 125,023; Better et al. (1988) *Science* 240:1041-1043; Liu

et al. (1987) *PNAS* 84:3439-3443; Liu et al. (1987) *J. Immunol.* 139:3521-3526; Sun et al. (1987) *PNAS* 84:214-218; Nishimura et al. (1987) *Canc. Res.* 47:999-1005; Wood et al. (1985) *Nature* 314:446-449; and Shaw et al. (1988) *J. Natl. Cancer Inst.* 80:1553-1559; Morrison, S. L. (1985) *Science* 229:1202-1207; Oi et al. (1986) *BioTechniques* 4:141:4053-4060; Winter U.S. Patent 5,225,539; Jones et al. (1986) *Nature* 321:552-525; Verhoeyan et al. (1988) *Science* 239:1534; and Beidler et al. (1988) *J. Immunol.* 141:4053-4060.

An anti-*Siva* antibody (e.g., monoclonal antibody) can be used to isolate *Siva* by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-*Siva* antibody can facilitate the purification of natural *Siva* from cells and of recombinantly produced *Siva* expressed in host cells. Moreover, an anti-*Siva* antibody can be used to detect *Siva* protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the *Siva* protein. Anti-*Siva* antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

IV. Pharmaceutical Compositions

The *Siva* nucleic acid molecules, *Siva* proteins, *Siva* modulators, and anti-*Siva* antibodies (also referred to herein as "active compounds") of the invention can be incorporated into pharmaceutical compositions suitable for administration to a subject, e.g., a human. Such compositions typically comprise the nucleic acid molecule, protein, modulator, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.

- 40 -

The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, such media can be used in the compositions of the invention.

Supplementary active compounds can also be incorporated into the compositions.

5 A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following
10 components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of
15 tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous
20 solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy
25 syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity
30 can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include
35 isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be

- 41 -

brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a *Siva* protein or anti-*Siva* antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

- 42 -

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see e.g., Chen et al. (1994) *PNAS* 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

V. Uses and Methods of the Invention

The nucleic acid molecules, polypeptides, polypeptide homologues, modulators, and antibodies described herein can be used in one or more of the following methods: 1) drug screening assays; 2) diagnostic assays; and 3) methods of treatment. A *Siva* protein of the invention has one or more of the activities described herein and can thus be used to, for example, modulate apoptosis, e.g., apoptosis of an immune cell. The isolated nucleic acid molecules of the invention can be used to express *Siva* protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect *Siva* mRNA (e.g., in a biological sample) or a genetic lesion in a *Siva* gene, and to modulate *Siva* activity, as described further below. In addition, the *Siva* proteins can be used to screen drugs or compounds which modulate *Siva* protein activity as well as to treat disorders characterized by insufficient production of *Siva* protein or production of *Siva* protein forms which have decreased activity compared to wild type *Siva*. Moreover, the anti-*Siva* antibodies of the invention can be used to detect and isolate *Siva* protein and modulate *Siva* protein activity.

a. Drug Screening Assays:

The invention provides methods for identifying compounds or agents which can be used to treat disorders characterized by (or associated with) aberrant or abnormal *Siva* nucleic acid expression and/or *Siva* protein activity. These methods are also referred to herein as drug screening assays and typically include the step of screening a candidate/test compound or agent for the ability to interact with (e.g., bind to) a *Siva* protein, to modulate the interaction of a *Siva* protein and a target molecule, and/or to modulate *Siva* nucleic acid expression and/or *Siva* protein activity. Candidate/test compounds or agents (e.g., candidate/test compounds which can restore or replace normal cell function/morphology in cells containing aberrant or abnormal *Siva* nucleic acid expression and/or *Siva* protein activity, candidate/test compounds that can bypass *Siva* functions) which have one or more of these abilities can be used as drugs to treat disorders characterized by aberrant or abnormal *Siva* nucleic acid expression and/or *Siva* protein activity. Candidate/test compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam, K.S. et al. (1991) *Nature* 354:82-84; Houghten, R. et al. (1991) *Nature* 354:84-86) and combinatorial chemistry-derived molecular libraries made of D- and/or L- configuration amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang, Z. et al. (1993) *Cell* 72:767-778); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab')₂, Fab expression

library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural product libraries).

In one embodiment, the invention provides assays for screening candidate/test compounds which interact with (e.g., bind to) *Siva* protein. Typically, the assays are cell-free assays which include the steps of combining a *Siva* protein or a biologically active portion thereof, and a candidate/test compound, e.g., under conditions which allow for interaction of (e.g., binding of) the candidate/test compound to the *Siva* protein or portion thereof to form a complex, and detecting the formation of a complex, in which the ability of the candidate compound to interact with (e.g., bind to) the *Siva* protein or fragment thereof is indicated by the presence of the candidate compound in the complex. Formation of complexes between the *Siva* protein and the candidate compound can be quantitated, for example, using standard immunoassays.

In another embodiment, the invention provides screening assays to identify candidate/test compounds which modulate (e.g., stimulate or inhibit) the interaction (and most likely *Siva* activity as well) between a *Siva* protein and a molecule (target molecule) with which the *Siva* protein normally interacts. An example of such a target molecule includes CD27 or a portion thereof, e.g., a cytoplasmic domain of CD27 and other proteins which may function upstream (including both stimulators and inhibitors of activity) or downstream of the *Siva* protein in an apoptosis signaling pathway. Typically, the assays are cell-free assays which include the steps of combining a *Siva* protein or a biologically active portion thereof, a *Siva* target molecule (e.g., CD27) and a candidate/test compound, e.g., under conditions wherein but for the presence of the candidate compound, the *Siva* protein or biologically active portion thereof interacts with (e.g., binds to) the target molecule, and detecting the formation of a complex which includes the *Siva* protein and the target molecule or detecting the interaction/reaction of the *Siva* protein and the target molecule. Detection of complex formation can include direct quantitation of the complex by, for example, measuring inductive effects of the *Siva* protein. A statistically significant change, such as a decrease, in the interaction of *Siva* and target molecule (e.g., in the formation of a complex between *Siva* and the target molecule) in the presence of a candidate compound (relative to what is detected in the absence of the candidate compound) is indicative of a modulation (e.g., stimulation or inhibition) of the interaction between the *Siva* protein and the target molecule. Modulation of the formation of complexes between the *Siva* protein and the target molecule can be quantitated using, for example, an immunoassay.

To perform the above drug screening assays, it is desirable to immobilize either *Siva* or its target molecule to facilitate separation of complexes from uncomplexed forms

- 45 -

of one or both of the proteins, as well as to accommodate automation of the assay. Interaction (e.g., binding of) of *Siva* to a target molecule, in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-
5 centrifuge tubes. In one embodiment, a fusion polypeptide can be provided which adds a domain that allows the polypeptide to be bound to a matrix. For example, glutathione-S-transferase/*Siva* fusion polypeptides can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g. ³⁵S-labeled) and the candidate compound, and
10 the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of
15 *Siva*-binding polypeptide found in the bead fraction quantitated from the gel using standard electrophoretic techniques.

Other techniques for immobilizing polypeptides on matrices can also be used in the drug screening assays of the invention. For example, either *Siva* or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin.
20 Biotinylated *Siva* molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with *Siva* but which do not interfere with binding of the polypeptide to its target molecule can be derivatized to the wells of the
25 plate, and *Siva* trapped in the wells by antibody conjugation. As described above, preparations of a *Siva*-binding polypeptide and a candidate compound are incubated in the *Siva*-presenting wells of the plate, and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes
30 using antibodies reactive with the *Siva* target molecule, or which are reactive with *Siva* polypeptide and compete with the target molecule; as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

In yet another embodiment, the invention provides a method for identifying a compound (e.g., a screening assay) capable of use in the treatment of a disorder
35 characterized by (or associated with) aberrant or abnormal *Siva* nucleic acid expression or *Siva* protein activity. This method typically includes the step of assaying the ability of the compound or agent to modulate the expression of the *Siva* nucleic acid or the

- 46 -

activity of the *Siva* protein thereby identifying a compound for treating a disorder characterized by aberrant or abnormal *Siva* nucleic acid expression or *Siva* protein activity. Disorders characterized by aberrant or abnormal *Siva* nucleic acid expression or *Siva* protein activity are described herein. Methods for assaying the ability of the compound or agent to modulate the expression of the *Siva* nucleic acid or activity of the *Siva* protein are typically cell-based assays. For example, cells which are sensitive to ligands which transduce signals via a pathway involving *Siva* can be induced to overexpress a *Siva* protein in the presence and absence of a candidate compound. Candidate compounds which produce a statistically significant change in *Siva*-dependent responses (either stimulation or inhibition) can be identified. In one embodiment, expression of the *Siva* nucleic acid or activity of *Siva* protein is modulated in cells and the effects of candidate compounds on the readout of interest (such as rate of cell proliferation, differentiation, death) are measured. For example, the expression of genes which are up- or down-regulated in response to a *Siva*-dependent signal cascade can be assayed. In preferred embodiments, the regulatory regions of such genes, e.g., the 5' flanking promoter and enhancer regions, are operably linked to a detectable marker (such as luciferase) which encodes a gene product that can be readily detected. Phosphorylation of *Siva* or *Siva* target molecules can also be measured, for example, by immunoblotting.

Alternatively, modulators of *Siva* expression (e.g., compounds which can be used to treat a disorder characterized by aberrant or abnormal *Siva* nucleic acid expression or *Siva* protein activity) can be identified in a method wherein a cell is contacted with a candidate compound and the expression of *Siva* mRNA or protein in the cell is determined. The level of expression of *Siva* mRNA or protein in the presence of the candidate compound is compared to the level of expression of *Siva* mRNA or polypeptide in the absence of the candidate compound. The candidate compound can then be identified as a modulator of *Siva* nucleic acid expression based on this comparison and be used to treat a disorder characterized by aberrant *Siva* nucleic acid expression. For example, when expression of *Siva* mRNA or polypeptide is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of *Siva* nucleic acid expression. Alternatively, when *Siva* nucleic acid expression is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of *Siva* nucleic acid expression. The level of *Siva* nucleic acid expression in the cells can be determined by methods described herein for detecting *Siva* mRNA or protein.

- 47 -

In yet another aspect of the invention, the *Siva* proteins can be used as "bait proteins" in a two-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos et al. (1993) *Cell* 72:223-232; Madura et al. (1993) *J. Biol. Chem.* 268:12046-12054; Bartel et al. (1993) *Biotechniques* 14:920-924; Iwabuchi et al. (1993) *Oncogene* 8:1693-1696; and Brent WO 94/10300), to identify other proteins, which bind to or interact with *Siva* ("Siva-binding proteins" or "Siva-bp") and modulate *Siva* protein activity. Such *Siva*-binding proteins are also likely to be involved in the propagation of signals by the *Siva* protein as, for example, upstream or downstream elements of the *Siva* pathway.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Bartel, P. et al. "Using the Two-Hybrid System to Detect Protein-Protein Interactions" in *Cellular Interactions in Development: A Practical Approach*, Hartley, D.A. ed. (Oxford University Press, Oxford, 1993) pp. 153-179. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for *Siva* is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified polypeptide ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a *Siva*-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., *LacZ*) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the polypeptide which interacts with *Siva*.

Modulators of *Siva* protein activity and/or *Siva* nucleic acid expression identified according to these drug screening assays can be used to treat, for example, proliferative disorders, e.g., proliferative disorders of immune cells and autoimmune diseases. These methods of treatment include the steps of administering the modulators of *Siva* protein activity and/or nucleic acid expression, e.g., in a pharmaceutical composition as described in subsection IV above, to a subject in need of such treatment, e.g., a subject with a disorder described herein.

b. Diagnostic Assays:

The invention further provides methods for detecting the presence of *Siva* in a biological sample. These methods involve contacting the biological sample with a compound or an agent capable of detecting *Siva* protein or mRNA. A preferred agent

- 48 -

for detecting *Siva* mRNA is a labeled or labelable nucleic acid probe capable of hybridizing to *Siva* mRNA. The nucleic acid probe can be, for example, the full-length *Siva* cDNA of SEQ ID NO: 1 or SEQ ID NO:3, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and
5 sufficient to specifically hybridize under stringent conditions to *Siva* mRNA. A preferred agent for detecting *Siva* protein is a labeled or labelable antibody capable of binding to *Siva* protein. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')₂) can be used. The term "labeled or labelable", with regard to the probe or antibody, is intended to encompass
10 direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with
15 fluorescently labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect *Siva* mRNA or polypeptide in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of *Siva* mRNA include Northern
20 hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of *Siva* protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. Alternatively, a *Siva* protein can be detected *in vivo* in a subject by introducing into the subject a labeled anti-*Siva* antibody. For example, the antibody can be labeled with a radioactive marker whose presence and
25 location in a subject can be detected by standard imaging techniques.

The invention also encompasses kits for detecting the presence of *Siva* in a biological sample. For example, the kit can comprise a labeled or labelable compound or agent capable of detecting *Siva* polypeptide or mRNA in a biological sample; means for determining the amount of *Siva* in the sample; and means for comparing the amount
30 of *Siva* in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect *Siva* mRNA or protein.

The methods of the invention can also be used to detect genetic lesions in a *Siva* gene, thereby determining if a subject with the lesioned gene is at risk for a disorder
35 characterized by aberrant or abnormal *Siva* nucleic acid expression or *Siva* protein activity as defined herein. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion

- 49 -

characterized by at least one of an alteration affecting the integrity of a gene encoding a *Siva* protein, or the misexpression of the *Siva* gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of 1) a deletion of one or more nucleotides from a *Siva* gene; 2) an addition of one or more nucleotides to a *Siva* gene; 3) a substitution of one or more nucleotides of a *Siva* gene, 4) a chromosomal rearrangement of a *Siva* gene; 5) an alteration in the level of a messenger RNA transcript of a *Siva* gene, 6) aberrant modification of a *Siva* gene, such as of the methylation pattern of the genomic DNA, 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of a *Siva* gene, 8) a non-wild type level of a *Siva*-protein, 9) allelic loss of a *Siva* gene, and 10) inappropriate post-translational modification of a *Siva*-protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a *Siva* gene.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al. (1988) *Science* 241:1077-1080; and Nakazawa et al. (1994) *PNAS* 91:360-364), the latter of which can be particularly useful for detecting point mutations in the *Siva*-gene (see Abravaya et al. (1995) *Nucleic Acids Res.* 23:675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a *Siva* gene under conditions such that hybridization and amplification of the *Siva*-gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample.

In an alternative embodiment, mutations in a *Siva* gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, for example, U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the *Siva* gene and detect mutations by comparing the sequence of the sample *Siva* with the corresponding wild-type (control) sequence.

Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert ((1977) *PNAS* 74:560) or Sanger ((1977) *PNAS* 74:5463). A variety of automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, 5 e.g., PCT International Publication No. WO 94/16101; Cohen et al. (1996) *Adv. Chromatogr.* 36:127-162; and Griffin et al. (1993) *Appl. Biochem. Biotechnol.* 38:147-159).

Other methods for detecting mutations in the *Siva* gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or 10 RNA/DNA duplexes (Myers et al. (1985) *Science* 230:1242); Cotton et al. (1988) *PNAS* 85:4397; Saleeba et al. (1992) *Meth. Enzymol.* 217:286-295), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita et al. (1989) *PNAS* 86:2766; Cotton (1993) *Mutat Res* 285:125-144; and Hayashi (1992) *Genet Anal Tech Appl* 9:73-79), and movement of mutant or wild-type fragments in polyacrylamide gels containing 15 a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (Myers et al (1985) *Nature* 313:495). Examples of other techniques for detecting point mutations include, selective oligonucleotide hybridization, selective amplification, and selective primer extension.

20 c. Methods of Treatment

Another aspect of the invention pertains to methods for treating a subject, e.g., a human, having a disease or disorder characterized by (or associated with) aberrant or abnormal *Siva* nucleic acid expression and/or *Siva* polypeptide activity. These methods include the step of administering a *Siva* modulator to the subject such that treatment 25 occurs. The language "aberrant or abnormal *Siva* expression" refers to expression of a non-wild-type *Siva* polypeptide or a non-wild-type level of expression of a *Siva* polypeptide. Aberrant or abnormal *Siva* activity refers to a non-wild-type *Siva* activity or a non-wild-type level of *Siva* activity. As the *Siva* polypeptide is involved in an apoptotic pathway, aberrant or abnormal *Siva* activity or expression interferes with the 30 normal apoptotic functions, e.g., apoptotic function in immune cells. Non-limiting examples of disorders or diseases characterized by or associated with abnormal or aberrant *Siva* activity or expression in immune cells include proliferative disorders such as malignant lymphomas, e.g., Non-Hodgkin's lymphomas, Hodgkin's disease, leukemias such as acute and chronic leukemias and other immune cells disorders 35 described in Robbins, S.L. et al. *Pathologic Basis of Disease*, 3rd ed. (W.B. Saunders Company, Philadelphia, 1984) pp. 653-704. Other non-limiting examples of disorders or diseases characterized by or associated with abnormal or aberrant *Siva* activity or

- 51 -

expression in immune cells include autoimmune diseases such as diabetes mellitus, arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis), multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, autoimmune thyroiditis, dermatitis (including atopic dermatitis and eczematous dermatitis), psoriasis, Sjögren's Syndrome, including keratoconjunctivitis sicca secondary to Sjögren's Syndrome, alopecia areata, allergic responses due to arthropod bite reactions, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, drug eruptions, leprosy reversal reactions, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Crohn's disease, Graves ophthalmopathy, sarcoidosis, primary biliary cirrhosis, uveitis posterior, and interstitial lung fibrosis). The terms "treating" or "treatment", as used herein, refer to reduction or alleviation of at least one adverse effect or symptom of a disorder or disease, e.g., a disorder or disease characterized by or associated with abnormal or aberrant *Siva* polypeptide activity and/or *Siva* nucleic acid expression.

As used herein, a *Siva* modulator is a molecule which can modulate *Siva* nucleic acid expression and/or *Siva* protein activity. For example, a *Siva* modulator can modulate, e.g., upregulate (activate) or downregulate (suppress), *Siva* nucleic acid expression. In another example, an *Siva* modulator can modulate (e.g., stimulate or inhibit) *Siva* protein activity. If it is desirable to treat a disorder or disease characterized by (or associated with) aberrant or abnormal (non-wild-type) *Siva* nucleic acid expression and/or *Siva* protein activity by inhibiting *Siva* nucleic acid expression, a *Siva* modulator can be an antisense molecule, e.g., a ribozyme, as described herein. Examples of antisense molecules which can be used to inhibit *Siva* nucleic acid expression include antisense molecules which are complementary to a portion of the 5' untranslated region of SEQ ID NO:1 or SEQ ID NO:3 which also includes the start codon and antisense molecules which are complementary to a portion of the 3' untranslated region of SEQ ID NO:1 or SEQ ID NO:3. A *Siva* modulator which inhibits *Siva* nucleic acid expression can also be a small molecule or other drug, e.g., a small molecule or drug identified using the screening assays described herein, which inhibits *Siva* nucleic acid expression. *Siva* modulators which inhibit *Siva* nucleic acid expression can be used to treat disorders for which it is desirable to increase immune cell survival.

- 52 -

Examples of such disorders include immunodeficiency diseases, such as primary immunodeficiencies (including, severe combined immunodeficiency, adenosine deaminase deficiency, purine nucleoside phosphorylase deficiency, MHC class II deficiency, reticular dysgenesis, X-linked agammaglobulinemia, X-linked hypogammaglobulinemia, Ig deficiency with increased IgM, Ig heavy chain-gene deletions, k-chain deficiency IgA deficiency, selective deficiency of IgG subclass, common variable immunodeficiency, transient hypogammaglobulinemia of infancy, Wiskott-Aldrich syndrome, ataxia telangiectasia, DiGeorge syndrome, Bloom syndrome, Fanconi anemia, and Down syndrome-related immunodeficiency, as well as other syndromes associated with immunodeficiency) and immunodeficiencies resulting from other causes, such as HIV disease/AIDS. In addition, *Siva* modulators which inhibit *Siva* nucleic acid expression can also be used to increase immune cell survival to thereby promote cellular responses to tumors, or pathogens, such as viruses, bacteria, fungi, and parasites.

If it is desirable to treat a disease or disorder characterized by (or associated with) aberrant or abnormal (non-wild-type) *Siva* nucleic acid expression and/or *Siva* protein activity by stimulating *Siva* nucleic acid expression, a *Siva* modulator can be, for example, a nucleic acid molecule encoding *Siva* (e.g., a nucleic acid molecule comprising a nucleotide sequence homologous to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3) or a small molecule or other drug, e.g., a small molecule (peptide) or drug identified using the screening assays described herein, which stimulates *Siva* nucleic acid expression. *Siva* modulators which promote *Siva* nucleic acid expression can be used to treat disorders for which it is desirable to decrease immune cell survival. Examples of such disorders include proliferative disorders as described herein, graft-versus-host disease, and allergy.

Alternatively, if it is desirable to treat a disease or disorder characterized by (or associated with) aberrant or abnormal (non-wild-type) *Siva* nucleic acid expression and/or *Siva* polypeptide activity by inhibiting *Siva* protein activity, a *Siva* modulator can be an anti-*Siva* antibody or a small molecule or other drug, e.g., a small molecule or drug identified using the screening assays described herein, which inhibits *Siva* protein activity. *Siva* modulators which inhibit *Siva* protein activity can be used to treat disorders for which it is desirable to increase immune cell survival. Examples of such disorders are described herein.

If it is desirable to treat a disease or disorder characterized by (or associated with) aberrant or abnormal (non-wild-type) *Siva* nucleic acid expression and/or *Siva* protein activity by stimulating *Siva* protein activity, a *Siva* modulator can be an active *Siva* protein or portion thereof (e.g., a *Siva* protein or portion thereof having an amino

- 53 -

acid sequence which is homologous to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or a portion thereof) or a small molecule or other drug, e.g., a small molecule or drug identified using the screening assays described herein, which stimulates *Siva* protein activity. *Siva* modulators which promote *Siva* protein activity can be used to treat disorders for which it is desirable to decrease immune cell survival. Examples of such disorders are described herein.

In addition, a subject having a proliferative disorder, e.g., a proliferative disorder of an immune cell can be treated according to the present invention by administering to the subject a *Siva* protein or portion thereof or a nucleic acid encoding a *Siva* protein or portion thereof such that treatment occurs. In addition, the *Siva* modulators of the invention can be used to inhibit metastasis of tumor cells to thereby further treat proliferative disorders. Similarly, a subject having autoimmune disorder or disease can be treated according to the present invention by administering to the subject a *Siva* protein or portion thereof or a nucleic acid encoding a *Siva* protein or portion thereof such that treatment occurs.

Other aspects of the invention pertain to methods for modulating a cell associated activity. These methods include contacting the cell with an agent (or a composition which includes an effective amount of an agent) which modulates *Siva* protein activity or *Siva* nucleic acid expression such that a cell associated activity is altered relative to a cell associated activity of the cell in the absence of the agent. As used herein, "a cell associated activity" refers to a normal or abnormal activity or function of a cell. Examples of cell associated activities include proliferation, migration, differentiation, production or secretion of molecules, such as proteins, and cell survival. In a preferred embodiment, the cell is an immune cell. The term "altered" as used herein refers to a change, e.g., an increase or decrease, of a cell associated activity. In one embodiment, the agent stimulates *Siva* protein activity or *Siva* nucleic acid expression. Examples of such stimulatory agents include an active *Siva* protein, a nucleic acid molecule encoding *Siva* that has been introduced into the cell, and a modulatory agent which stimulates *Siva* protein activity or *Siva* nucleic acid expression and which is identified using the drug screening assays described herein. In another embodiment, the agent inhibits *Siva* protein activity or *Siva* nucleic acid expression. Examples of such inhibitory agents include an antisense *Siva* nucleic acid molecule, an anti-*Siva* antibody, and a modulatory agent which inhibits *Siva* protein activity or *Siva* nucleic acid expression and which is identified using the drug screening assays described herein. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). In a preferred embodiment, the modulatory methods are performed *in vivo*, i.e., the cell is

- 54 -

present within a subject, e.g., a mammal, e.g., a human, and the subject has a disorder or disease characterized by or associated with abnormal or aberrant *Siva* protein activity or *Siva* nucleic acid expression.

5 A nucleic acid molecule, a polypeptide, a *Siva* modulator, a compound etc. used in the methods of treatment can be incorporated into an appropriate pharmaceutical composition described herein and administered to the subject through a route which allows the molecule, polypeptide, modulator, or compound etc. to perform its intended function. Examples of routes of administration are also described herein under subsection IV.

10 The present invention is further illustrated by the following examples which should not be construed as limiting. The contents of all cited references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference.

15 EXAMPLES

The following materials and methods were used in the Examples:

Plasmids and transfectants

20 The generation of mock, human CD27 and human CD70 transfectants in the murine pre-B 300-19 cell line has been described elsewhere (Kobata, T. et al. (1994) *J. Immunol.* 153:5422-5432; Kobata, T. et al. (1995) *PNAS* 92:11249-11253). CD27 cytoplasmic tail (residues 192-240) was subcloned in frame at the 3' end of the Gal4 DNA binding domain of the yeast shuttle vector pAS2 at the NdeI and BamHI sites.
25 CD27WT (full length) was subcloned into the RcCMV vector at the Hind3 and XbaI sites. *Siva-1* sequence (nucleotides 1-567) was fused in frame to the C-terminus of GFP using the EcoRI site in the pEGFPC1 plasmid (Clontech, Palo Alto, CA). Since PCR was used to generate specific restriction sites, all the fusions constructed were confirmed by sequencing the coding frame.

30 Yeast two hybrid screening

The procedures followed were essentially according to the manufacture's instructions (Clontech manual, Palo Alto, CA). The yeast strain HF7C was transfected with pAS2CD27CT and pGADGH2 containing the HeLa cDNA library. Potential
35 CD27CT interacting clones were selected based on their ability to grow in the absence of Leu, Tyr and His and for their capacity to turn blue in the presence of X-gal. Positive colonies were picked and the library derived plasmids were recovered by transforming

- 55 -

HB101 bacteria grown on minimal plates in the presence of ampicillin and absence of Leu. The interacting clones were confirmed by re-transfecting HF7C along with the pAS2CD27CT. A GenBank search with the DNA and protein sequence of H2 confirmed that it was novel. The H2 insert was then used to screen a HeLa cDNA (λ zap1) and a 5' stretch human thymus cDNA (λ gt11) library to obtain the full length *Siva-1* cDNA. All the vectors and libraries were purchased from Clontech, Palo Alto, CA.

Northern blot analysis and transient transfections

Pre-made Northern blots (2 μ g of poly(A)+ RNA/lane) representing various human tissues and cell lines (Clontech, Palo Alto, CA) were probed with the H2 insert labeled with 32 P-ATP using the Quick Prime kit (Pharmacia, Piscataway, NJ). Both pre-hybridization and hybridization were carried out at 42°C in the presence of formamide. Suspension cells were transfected using the lipofectamine reagent (Life Technologies, Gaithersburg, MD). Adherent cells were transfected using the calcium phosphate procedure. Transfection efficiencies with both procedures ranged from 15-20%.

DNA fragmentation assay

Cells were lysed (0.4% Triton X-100, 4 mM EDTA in 25 mM Tris pH 7.5). Supernatant was treated with phenol:chloroform and the DNA precipitated. Prior to separation of DNA on agarose, it was treated with RNase.

Immunoprecipitations and Western blotting

293 cells (transformed, human embryonal kidney cells) were detached using PBS containing 2mM EDTA, collected and lysed (1% NP40 and 150 mM NaCl in 20 mM Tris pH 7.5) in the presence of protease inhibitors. Supernatant was precleared with anti-mouse Ig coupled to sepharose beads and immunoprecipitation was carried out using anti-CD27 monoclonal antibody (IA4, 3 μ g/ml) and anti-mouse IgG beads. Whole cell lysates were prepared using RIPA buffer (1% NP40, 1% DOC and 0.1% SDS). Proteins were separated on 12% SDS-PAGE, transferred to a nitrocellulose membrane, blocked with 3% BSA and immunoblotted with anti-GFP rabbit antiserum (1:1000) and developed using the ECL reagent

EXAMPLE I: CD27 EFFECTS CELLULAR APOPTOSIS

Although several of the TNFR family members are known to induce apoptosis (Smith, C.A. et al. (1994) *Cell* 76:959-962), there has been no report to date as to whether CD27 is capable of effecting this cell function. In order to test this, Ramos, a B

- 56 -

cell line which expresses high levels of surface CD27 was cultured at relatively low cell density for 2 days with varying concentrations of live CD70 or mock transfectants.

Apoptosis was only observed after culture in the presence of CD70 transfectants, as assessed by DNA fragmentation. Under similar conditions, no fragmented DNA was
5 observed when Ramos, mock and CD70 transfectant cells were cultured alone.

In order to be certain that CD27-bearing cells and not the transfectant cells were undergoing apoptosis, the experiment was repeated using the same transfectants fixed with formaldehyde. Once again, pre-fixed CD70 transfectants but not the mock
10 transfectants were capable of inducing apoptosis in Ramos, Raji, another B cell line, although this effect was less pronounced using the CD27 transfectant. Pre-fixing the transfectants and/or culturing the cells alone did not result in DNA fragmentation.

Since ligation of surface IgM in activated B cells is also known to cause cell death (Tsubata, T. et al. (1993) *Nature* 364:645-648; Valentine, M.A. and Licciardi, K.A. (1992) *Eur. J. Immunol.* 22:3141-3148), experiments were performed to determine
15 whether co-ligation of CD27 would enhance this effect. It was found that co-culture with CD70 transfectants and ligation of surface Ig receptors resulted in marked enhancement in cell death in Ramos and CD27 transfectant but was not apparent in Raji cells. Ligation of CD27 induces apoptosis in normal human peripheral blood lymphocytes (PBLs) pre-activated with PHA and IL2.

The B cell lines Ramos and Raji express on their surface relatively high levels of both CD27 and CD70 but do not undergo apoptosis under normal cell culture
20 conditions. This could be due to the relatively low cell density used for routine cell culture, which may not permit the interaction between CD27 and CD70 to reach the requisite threshold. In the experimental conditions described herein, the amount of available CD70 to Ramos cell cultures is increased by several orders of magnitude, thus
25 overcoming the threshold barrier and resulting in apoptosis of CD27-bearing cells. This is supported by the observation that Ramos or Raji cells grown to relatively high cell density ($> 1.0 \times 10^6$ cells/ml), results in increased background apoptosis even in the presence of optimum amounts of nutrients.

B-cell cancers such as Non-Hodgkin's lymphoma and B-CLL do not undergo
30 apoptosis, despite the high expression of both CD27 and CD70. This could be due to the fact that these cells release soluble CD27 (sCD27) (Ranheim, E.A. et al. (1995) *Blood* 85:3556-356; Van Oers, M.H. et al. (1993) *Blood* 82:3430-3436), which builds up in the body fluids, and possibly disrupts CD27-mediated apoptosis. Disruption of the
35 binding between CD27 and CD70 by sCD27 is also likely to aid in metastasis, thus playing an accelerating role in the progress of these cancers.

- 57 -

EXAMPLE II: IDENTIFICATION AND CHARACTERIZATION OF THE HUMAN *SIVA-1* GENE

The cytoplasmic tail of CD27 (CD27CT) is highly conserved between man and mouse (Camerini, D. et al. (1991) *J. Immunol.* 147:3165-3169; Gravestien, L.A. et al. (1993) *Eur. J. Immunol.* 23:943-950) suggesting its importance for the receptor function. In this example, the CD27CT was used as the bait for screening a HeLa cell cDNA library using the yeast two hybrid system. The Epstein-Barr virus transforming protein, LMP1 and its binding protein, Lap1 (TRAF3/CRAF) coding plasmids were used as the positive control in the yeast system (Valentine, M.A. and Licciardi, K.A. (1992) *Eur. J. Immunol.* 22:3141-3148). Transfection of the yeast strain HF7C with pAS2LMP1 and pGADLap1 plasmids gave several robust colonies when selected on plates lacking Leu, Tyr and His and all of them turned blue in the presence of x-gal. One clone, H2, co-transfected with the CD27CT plasmid gave several slow growing slightly smaller size colonies that turned blue in the presence of x-gal, but not when transfected together with the LMP1 plasmid, clearly suggesting the preferential interaction between the CD27CT and H2 (Table 1).

TABLE 1
GROWTH AND INDUCTION OF β -GALACTOSIDASE IN THE YEAST STRAIN HF7C IN THE ABSENCE OF LEU, TYR, AND HIS

	pAS2LMP1		pAS2CD27CT	
	<u>Colonies</u>	<u>Blue Color</u>	<u>Colonies</u>	<u>Blue Color</u>
pGADLAP1	++++	++++	None	—
pGADH2*	None	—	++	+++

*H2 related clones H1 and H7 also gave similar results. pAS2CD27CT and pGADH2 transfectants grown in the absence of Tyr and Leu respectively, did not turn blue in the presence of x-Gal.

Of the several positive clones, a GenBank search identified the clone H2 as novel. Full length cDNA sequence was obtained by further screening HeLa cell and human thymocyte cDNA libraries using the H2 insert from the pGADH2 plasmid. Translation of the open reading frame revealed the primary sequence to be 189 amino acids long (Figure 1; SEQ ID NO:2). The initiation codon is defined by the upstream in-

- 58 -

frame stop codon (starting at nucleotide -42 in Figure 1 (nucleotide 42 in SEQ ID NO:1)). The coding region is followed by a stop codon (starting at nucleotide 568 in Figure 1 (nucleotide 700 in SEQ ID NO:1)), a polyadenylation signal (nucleotides 709 to 714 in Figure 1 (nucleotides 841 to 846 of SEQ ID NO:1)). The protein having this amino acid sequence was designated "*Siva*" (after the Hindu god of destruction). As a putative splice variant of this protein was also identified, this *Siva* protein was designated "*Siva-1*". The nucleotide sequence encoding this protein is also referred to herein as "*Siva-1*" nucleic acid (Figure 1; SEQ ID NO:1) and has been deposited with GenBank under Accession Number U2938.

Analysis of the *Siva-1* primary amino acid sequence revealed an amino terminal region that has homology to the death domains of FADD and RIP. The alignment and homology calculations were determined using the program Clustal, where the amino acid size is also taken into consideration. The *Siva-1* protein also shares homology with the death domain of TRADD (Hsu, H. et al. (1995) *Cell* 81:495-504).

The carboxy terminal region of *Siva-1* is rich in cysteines and forms a B-Box like ring finger (amino acid residues 128-159 of SEQ ID NO:2 also shown as a separate sequence identification number SEQ ID NO:9) (Freemont, P.S. (1993) *Ann. N.Y. Acad. Sci.* 684:174-192). The B-Box region of *Siva-1*, however, lacks histidine. The amino terminal ring finger and the carboxy terminal coiled-coil domain structures, which are characteristic of other B-Box-containing proteins (Freemont, P.S. (1993) *Ann. N.Y. Acad. Sci.* 684:174-192), are absent in *Siva-1*. Instead, *Siva-1* is flanked by additional cysteine residues in the carboxy terminus that can form a zinc finger (amino acid residues 164-184 of SEQ ID NO:2 also shown as a separate sequence identification number SEQ ID NO:8), which also lacks histidine. Alternately, the cysteine rich region of *Siva-1* can represent a novel metal binding motif involved in either protein-protein or protein-DNA interactions. The architecture of *Siva-1* is unlike any of the molecules so far known to bind to the cytoplasmic tails of other TNFR family members.

EXAMPLE III: TISSUE EXPRESSION OF THE HUMAN *SIVA-1* GENE

Multiple human tissue northern blot analysis revealed the presence of varying amounts of 0.8 kb *Siva-1* mRNA in all the represented tissues including spleen, thymus, prostate, testis, ovary, small intestine, colon, and peripheral blood lymphocytes as well as several cell lines including HeLa cells (ATCC Accession No. CCL 2: human cervical carcinoma cell line), Raji cells (ATCC Accession No. CCL 86: human Burkitt lymphoma cell line), HL60 cells (ATCC Accession No. CCL 240: human promyelocyte cell line), K562 cells (ATCC Accession No. CCL 243: human erythroleukemia cell

- 59 -

line), MOTL-4 cells (ATCC Accession No. CRL 1582: human acute lymphoblastic leukemia cell line), SW480 cells (ATCC Accession No. CCL 228: human colorectal adenocarcinoma cell line), A549 cells (ATCC Accession No. CCL 185: human lung carcinoma cell line), and G-361 cells (ATCC Accession No. CRL 1424: human malignant melanoma cell line). Maximum mRNA expression was seen in thymus and the least in colon.

EXAMPLE IV: EXPRESSION OF RECOMBINANT HUMAN *SIVA-1* PROTEIN IN HUMAN CELLS

Although the results from the yeast two hybrid assay described above suggests a direct interaction between the CD27 cytoplasmic tail and *Siva-1*, the association between the two molecules was confirmed by transiently expressing (2 days) CD27WT (full length) DNA and *Siva-1* fused to the bacterial green fluorescence protein (GFP-*Siva-1*) and GFP alone in 293 embryonal renal cells. Cell lysates were prepared using mild non-ionic detergent like NP-40 and the CD27 receptor complexes were immunoprecipitated using anti-CD27 monoclonal antibody (1A4). The expression of GFP-*Siva* and GFP were similar as determined from the anti-GFP immunoblot. CD27 was found to co-precipitate GFP-*Siva-1* but not GFP.

EXAMPLE V: OVEREXPRESSION OF *SIVA-1* INDUCES APOPTOSIS

Since CD27 induces cell death and since its binding protein, *Siva-1*, has a region with significant homology to the death domains, experiments were performed to determine ether overexpression of *Siva-1* causes significant cellular apoptosis. GFP and GFP-*Siva-1* were transiently expressed in Jurkat, Raji, SKW, Ramos and 293 cell lines for two days and the percentage of dead cells that were fluorescing green was measured. In general, most of the cells expressing GFP-*Siva-1* looked unhealthy, very small, and with an irregular cell border when compared with cells expressing GFP. In every cell line tested, the percentage of GFP-*Siva-1* transfected dead cells were 2-3 times higher on comparison with those transfected with GFP alone. In the case of the adherent cell line 293, the β -galactosidase gene was expressed along with GFP and GFP-*Siva-1*. β -galactosidase expression was visualized by x-gal and cell morphology was examined using the light microscope. Most of the cells expressing GFP-*Siva-1* were much smaller and rounded (devoid of the cellular processes), clearly suggesting apoptosis. That this indeed is the case was confirmed by DNA fragmentation assay in 293 (adherent) and murine pre-B cell line (suspension). Electron microscopy performed on GFP and GFP-

- 60 -

Siva-1 transfected 293 cells revealed the presence of cells with apoptotic bodies only in GFP-*Siva-1* transfectants.

Thus, interaction between CD27 and CD70 is sufficient to elicit the apoptotic function of CD27. In the absence of crucial complementary signals, it is likely that engagement of CD27, especially in activated T and B cells that express CD27 and CD70, results in apoptosis. In situations of chronic activation, CD27-induced apoptosis likely plays an important role in maintaining self-tolerance and keeping in check activated T and B cells, which may contribute to some autoimmune diseases. In the case of multiple sclerosis, where elevated levels of soluble CD27 (sCD27) have been reported, it is possible that these elevations inhibit the regulatory or other effects of CD70 expressing T and B cells (Hinzmen, R.Q. et al. (1991) *J. Neuroimmunol.* 35:211-218).

EXAMPLE VI: IDENTIFICATION OF THE HUMAN *SIVA-2* GENE

While screening a human thymus cDNA library in an attempt to obtain a full length H2 clone, a second *Siva* gene, designated *Siva-2*, was identified. Upon comparing of their nucleotide sequences, the nucleotide sequence of *Siva-2* was found to be the same as that of *Siva-1* except for an in-frame deletion of nucleotides 157-351 spanning most of the death domain homology region. Thus, *Siva-2* appears to be an alternate splice form of *Siva-1*.

To confirm that *Siva-2* mRNA exists, RTPCR, using a 5' forward primer spanning the very beginning of *Siva-1* and a 3' reverse primer matching the 3' end of *Siva-1*, was performed on RNA (treated extensively with DNase) samples obtained from 293, Raji, HeLa, and thymus cells. The existence of two forms of *Siva*, an abundant form at about 600 bp (*Siva-1*) and a less abundant form at about 400 bp (*Siva-2*) was apparent in both thymus and Raji cells. The nucleotide sequence of *Siva-2* is shown in SEQ ID NO:3 and the deduced amino acid sequence is shown in SEQ ID NO:4.

Thus far, two types of molecules that interact with various TNFR family members have surfaced. One group comprises the death domain containing proteins- TRADD, FADD and RIP which interact with Fas and TNFRI (Hsu, H. et al. (1995) *Cell* 81:505-512; Chinnaiyan, A.M. et al. (1995) *Cell* 81:505-512; Stanger, Z.B. et al. (1995) *Cell* 81:513-523; Hsu, H. et al. (1996) *Immunity* 4:387-396). TRAFs form the second group, characterized by the zinc finger domains and interact with TNFRII, CD40 and LMP1 (Mosialos, G. et al. (1995) *Cell* 80:389-399; Rothe, M. et al. (1995) *Science* 269:1424-1427; Hsu, H et al. (1994) *J. Biol. Chem.* 269:30069-30072; Cheng, G. et al.

- 61 -

(1995) *Science* 267:1594-1498). In comparison, *Siva* does not appear to fall into either of these categories. Using the Clustal program that takes into consideration both the size and hydrophobicity of amino acids, a region in *Siva* homologous to the known death domains of FADD and RIP was identified. Although overall homology between the three is high, identical homology is low. Dendrogram analysis clearly places *Siva* outside all of the known DD containing proteins. The homologies reported here are comparable to those calculated for TRADD/FADD and TRADD/RIP and are higher than those for the DD of Reaper and other DD containing proteins (Cleveland, J.L. and Ihle, J.N. (1995) *Cell* 81:479-482). NMR structure of Fas DD revealed the presence of six antiparallel, amphipathic α helices, and a similar structure has been proposed for other DDs (Huang, B. et al. (1996) *Nature* 384:638-641). However, based on secondary structure predictions, the DDHR of *Siva* appears to lack at least 4 of these helices and thus could possibly be structurally different from that of the DD of Fas and its distant relative Reaper. An important consideration is that all DDs do not appear to be similar in terms of cellular function. For example, the DD of FADD is required for binding of FADD to FAS DD, but not for induction of apoptosis (Stanger, Z.B. et al. (1995) *Cell* 81:513-523; Grimm, S. et al. (1996) *PNAS* 93:10923-10927). TRADD DD however is required for eliciting both apoptosis and activation of the transcription factor NFkB (Chinnaiyan, A.M. et al. (1995) *Cell* 81:505-512; Park, A. and Baichwal, R. (1996) *J. Biol. Chem.* 271:9858-9862). In case of the *Drosophila* protein Reaper, mutations carried out in the DD region similar to that of Fas DD, does not abrogate the potent apoptotic activity of the protein (Chen, P. et al. (1996) *J. Biol. Chem.* 271:25735-25737).

- 62 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5 (i) APPLICANT:

(A) NAME: DANA-FARBER CANCER INSTITUTE

(B) STREET: 44 BINNEY STREET

(C) CITY: BOSTON

(D) STATE: MASSACHUSETTS

10 (E) COUNTRY: US

(F) POSTAL CODE: 02115

(G) TELEPHONE:

(H) TELEFAX:

15 (ii) TITLE OF INVENTION: THE SIVA GENES, NOVEL GENES INVOLVED
IN CD27-MEDIATED APOPTOSIS

(iii) NUMBER OF SEQUENCES: 12

20 (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: LAHIVE & COCKFIELD, LLP

(B) STREET: 28 STATE STREET

(C) CITY: BOSTON

(D) STATE: MASSACHUSETTS

25 (E) COUNTRY: US

(F) ZIP: 02109-1875

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

30 (B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

35 (A) APPLICATION NUMBER: PCT/US98/

(B) FILING DATE: 28 MAY 1998

(C) CLASSIFICATION:

- 63 -

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/865,297

(B) FILING DATE: 29 MAY 1997

5 (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: MANDRAGOURAS, AMY E.

(B) REGISTRATION NUMBER: 36,207

(C) REFERENCE/DOCKET NUMBER: DFN-024PC

10 (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (617) 227-7400

(B) TELEFAX: (617) 742-4214

(2) INFORMATION FOR SEQ ID NO:1:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 885 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

20

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(v) FRAGMENT TYPE: internal

25

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 133..699

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AGCCAAGCGT GGTGGCATGT GCCTGTAATC CCAGCTACTC AGGAGGCTGA GGCATGAGAA 60

TCTCTTGAAC CCCAGAGGTG TAGGTTGCAG TGAGCAGAGA TTGTGCCACT GCACTCCAGC 120

35

- 64 -

	CTGGGCGACA GC ATG AGG CGG CCG GGG AGC TGC GTA GCT CCC GGC CCC	168
	Met Arg Arg Pro Gly Ser Cys Val Ala Pro Gly Pro	
	1 5 10	
5	GCG GCC ATG CCC AAG CGG AGC TGC CCC TTC GCG GAC GTG GCC CCG CTA	216
	Ala Ala Met Pro Lys Arg Ser Cys Pro Phe Ala Asp Val Ala Pro Leu	
	15 20 25	
	CAG CTC AAG GTC CGC GTG AGC CAG AGG GAG TTG AGC CGC GGC GTG TGC	264
10	Gln Leu Lys Val Arg Val Ser Gln Arg Glu Leu Ser Arg Gly Val Cys	
	30 35 40	
	GCC GAG CGC TAC TCG CAG GAG GTC TTC GAG AAG ACC AAG CGA CTC CTG	312
	Ala Glu Arg Tyr Ser Gln Glu Val Phe Glu Lys Thr Lys Arg Leu Leu	
15	45 50 55 60	
	TTC CTC GGG GCC CAG GCC TAC CTG GAC CAC GTG TGG GAT GAA GGC TGT	360
	Phe Leu Gly Ala Gln Ala Tyr Leu Asp His Val Trp Asp Glu Gly Cys	
	65 70 75	
20		
	GCC GTC GTT CAC CTG CCA GAG TCC CCA AAG CCT GGC CCT ACA GGG GCC	408
	Ala Val Val His Leu Pro Glu Ser Pro Lys Pro Gly Pro Thr Gly Ala	
	80 85 90	
25	CCG AGG GCT GCA CGT GGG CAG ATG CTG ATT GGA CCA GAC GGC CGC CTG	456
	Pro Arg Ala Ala Arg Gly Gln Met Leu Ile Gly Pro Asp Gly Arg Leu	
	95 100 105	
	ATC AGG AGC CTT GGG CAG GCC TCC GAA GCT GAC CCA TCT GGG GTA GCG	504
30	Ile Arg Ser Leu Gly Gln Ala Ser Glu Ala Asp Pro Ser Gly Val Ala	
	110 115 120	
	TCC ATT GCC TGT TCC TCA TGC GTG CGA GCC GTG GAT GGG AAG GCG GTC	552
	Ser Ile Ala Cys Ser Ser Cys Val Arg Ala Val Asp Gly Lys Ala Val	
35	125 130 135 140	

- 65 -

TGC GGT CAG TGT GAG CGA GCC CTG TGC GGG CAG TGT GTG CGC ACC TGC 600
 Cys Gly Gln Cys Glu Arg Ala Leu Cys Gly Gln Cys Val Arg Thr Cys
 145 150 155

5 TGG GGC TGC GGC TCC GTG GCC TGT ACC CTG TGT GGC CTC GTG GAC TGC 648
 Trp Gly Cys Gly Ser Val Ala Cys Thr Leu Cys Gly Leu Val Asp Cys
 160 165 170

AGT GAC ATG TAC GAG AAA GTG CTG TGC ACC AGC TGT GCC ATG TTC GAG 696
 10 Ser Asp Met Tyr Glu Lys Val Leu Cys Thr Ser Cys Ala Met Phe Glu
 175 180 185

ACC TGAGGCTGGC TCAAGCCGGC TGCCTTCACC GGGAGCCACG CCGTG CATGG 749
 Thr
 15

CAGCCTTCCC TGGACGAGCG CTCGGTGTTT AGTGGGGTCG ACGGGAGGGG TGCCTTTTAC 809

ATGTTCTATT TTGTATCCTA ATGACAGAAT GAATAAACCT CTTTATATTT GCAAAAAAAAA 869

20 AAAAAAAAAA CTCGAG 885

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 189 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Arg Arg Pro Gly Ser Cys Val Ala Pro Gly Pro Ala Ala Met Pro
 1 5 10 15

35 Lys Arg Ser Cys Pro Phe Ala Asp Val Ala Pro Leu Gln Leu Lys Val
 20 25 30

- 66 -

Arg Val Ser Gln Arg Glu Leu Ser Arg Gly Val Cys Ala Glu Arg Tyr
 35 40 45

5 Ser Gln Glu Val Phe Glu Lys Thr Lys Arg Leu Leu Phe Leu Gly Ala
 50 55 60

Gln Ala Tyr Leu Asp His Val Trp Asp Glu Gly Cys Ala Val Val His
 65 70 75 80

10 Leu Pro Glu Ser Pro Lys Pro Gly Pro Thr Gly Ala Pro Arg Ala Ala
 85 90 95

Arg Gly Gln Met Leu Ile Gly Pro Asp Gly Arg Leu Ile Arg Ser Leu
 15 100 105 110

Gly Gln Ala Ser Glu Ala Asp Pro Ser Gly Val Ala Ser Ile Ala Cys
 115 120 125

20 Ser Ser Cys Val Arg Ala Val Asp Gly Lys Ala Val Cys Gly Gln Cys
 130 135 140

Glu Arg Ala Leu Cys Gly Gln Cys Val Arg Thr Cys Trp Gly Cys Gly
 145 150 155 160

25 Ser Val Ala Cys Thr Leu Cys Gly Leu Val Asp Cys Ser Asp Met Tyr
 165 170 175

Glu Lys Val Leu Cys Thr Ser Cys Ala Met Phe Glu Thr
 30 180 185

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 690 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

- 67 -

(ii) MOLECULE TYPE: cDNA

(v) FRAGMENT TYPE: internal

5 (ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 133..504

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

10

AGCCAAGCGT GGTGGCATGT GCCTGTAATC CCAGCTACTC AGGAGGCTGA GGCATGAGAA 60

TCTCTTGAAC CCCAGAGGTG TAGGTTGCAG TGAGCAGAGA TTGTGCCACT GCACTCCAGC 120

15 CTGGGCGACA GC ATG AGG CGG CCG GGG AGC TGC GTA GCT CCC GGC CCC 168

Met Arg Arg Pro Gly Ser Cys Val Ala Pro Gly Pro

1

5

10

GCG GCC ATG CCC AAG CGG AGC TGC CCC TTC GCG GAC GTG GCC CCG CTA 216

20 Ala Ala Met Pro Lys Arg Ser Cys Pro Phe Ala Asp Val Ala Pro Leu

15

20

25

CAG CTC AAG GTC CGC GTG AGC CAG AGG GAG TTG AGC CGC GGC GTG TGC 264

Gln Leu Lys Val Arg Val Ser Gln Arg Glu Leu Ser Arg Gly Val Cys

25 30

35

40

GCC GAG CGC TAC TCG CAG GAG GTC TTC GAC CCA TCT GGG GTA GCG TCC 312

Ala Glu Arg Tyr Ser Gln Glu Val Phe Asp Pro Ser Gly Val Ala Ser

45

50

55

60

30

ATT GCC TGT TCC TCA TGC GTG CAA GCC GTG GAT GGG AAG GCG GTC TGC 360

Ile Ala Cys Ser Ser Cys Val Arg Ala Val Asp Gly Lys Ala Val Cys

65

70

75

35 GGT CAG TGT GAG CGA GCC CTG TGC GGG CAG TGT GTG CGC ACC TGC TGG 408

Gly Gln Cys Glu Arg Ala Leu Cys Gly Gln Cys Val Arg Thr Cys Trp

80

85

90

- 68 -

GGC TGC GGC TCC GTG GCC TGT ACC CTG TGT GGC CTC GTG GAC TGC AGT 456
 Gly Cys Gly Ser Val Ala Cys Thr Leu Cys Gly Leu Val Asp Cys Ser
 95 100 105

5

GAC ATG TAC GAG AAA GTG CTG TGC ACC AGC TGT GCC ATG TTC GAG ACC 504
 Asp Met Tyr Glu Lys Val Leu Cys Thr Ser Cys Ala Met Phe Glu Thr
 110 115 120

10

TGAGGCTGGC TCAAGCCGGC TGCCTTCACC GGGAGCCACG CCGTGCATGG CAGCCTTCCC 564
 TGGACGAGCG CTCGGTGTTC AGTGGGGTCG ACGGAGGGG TGCCTTTTAC ATGTTCTATT 624
 TTGTATCCTA ATGACAGAAT GAATAAACCT CTTTATATTT GCAAAAAAAAA AAAAAAAAAA 684

15

CTCGAG 690

(2) INFORMATION FOR SEQ ID NO:4:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 124 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Arg Arg Pro Gly Ser Cys Val Ala Pro Gly Pro Ala Ala Met Pro
 30 1 5 10 15
 Lys Arg Ser Cys Pro Phe Ala Asp Val Ala Pro Leu Gln Leu Lys Val
 20 25 30
 35 Arg Val Ser Gln Arg Glu Leu Ser Arg Gly Val Cys Ala Glu Arg Tyr
 35 40 45

- 69 -

Ser Gln Glu Val Phe Asp Pro Ser Gly Val Ala Ser Ile Ala Cys Ser
50 55 60

Ser Cys Val Arg Ala Val Asp Gly Lys Ala Val Cys Gly Gln Cys Glu
5 65 70 75 80

Arg Ala Leu Cys Gly Gln Cys Val Arg Thr Cys Trp Gly Cys Gly Ser
85 90 95

10 Val Ala Cys Thr Leu Cys Gly Leu Val Asp Cys Ser Asp Met Tyr Glu
100 105 110

Lys Val Leu Cys Thr Ser Cys Ala Met Phe Glu Thr
115 120

15

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 770 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

25

(ix) FEATURE:

- (A) NAME/KEY: CDS
(B) LOCATION: 88..612

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

30

TTTGGCTCCG AGGCCAAGAA TTCGGCACGA GGGCTCGGCG CGCGGCGCGC TGC GCGCTGC 60

TGAAGGCTGT GTCTGGTACC CGCTACC ATG CCC AAG CGG AGC TGC CCG TTC 111

Met Pro Lys Arg Ser Cys Pro Phe

35

1

5

- 70 -

	GCA GAC GCA GCC CCG CTC CAA CTC AAA GTC CAC GTG GGC CTG AAA GAG	159
	Ala Asp Ala Ala Pro Leu Gln Leu Lys Val His Val Gly Leu Lys Glu	
	10 15 20	
5	CTG AGC CAC GGT GTG TTC GCC GAG CGC TAC TCA CGC GAG GTC TTC GAA	207
	Leu Ser His Gly Val Phe Ala Glu Arg Tyr Ser Arg Glu Val Phe Glu	
	25 30 35 40	
	AGA ACC AAG CAG CTC CTT TTC CAA GGG GCT CGG GCC TAT AGA GAT CAC	255
10	Arg Thr Lys Gln Leu Leu Phe Gln Gly Ala Arg Ala Tyr Arg Asp His	
	45 50 55	
	ATA TCG AGC GAA GAT TGT TCC GTG AAC CAC CTG CAG GAG TCA CTG AAG	303
	Ile Ser Ser Glu Asp Cys Ser Val Asn His Leu Gln Glu Ser Leu Lys	
15	60 65 70	
	TCT GGT GTG GTA GGA GCC CCT CAA CCT GCG AGG GGA CAG ATG TTG ATT	351
	Ser Gly Val Val Gly Ala Pro Gln Pro Ala Arg Gly Gln Met Leu Ile	
	75 80 85	
20	GGA CCT GAT GGC CGA CTG ACA CGG TGC CAA GCT CAG GCC TCA GAA GGT	399
	Gly Pro Asp Gly Arg Leu Thr Arg Cys Gln Ala Gln Ala Ser Glu Gly	
	90 95 100	
25	GGC CTT CCC AGG ACA GCG CCC ATC GCT TGT TCA TCG TGC ATG AGA TCT	447
	Gly Leu Pro Arg Thr Ala Pro Ile Ala Cys Ser Ser Cys Met Arg Ser	
	105 110 115 120	
	GTG GAT GGG AAG GCG GTC TGC AGC CAG TGC GAG CGG GCC CTG TGT GGG	495
30	Val Asp Gly Lys Ala Val Cys Ser Gln Cys Glu Arg Ala Leu Cys Gly	
	125 130 135	
	CAG TGT GTA TAC ACC AGC TGG GGC TGC GGT GCT TTG GCC TGT GTG CTG	543
	Gln Cys Val Tyr Thr Ser Trp Gly Cys Gly Ala Leu Ala Cys Val Leu	
35	140 145 150	

- 71 -

TGT GGC CTT GCA GAC TAT GCC GAC GAT GGT GAG AAG ACA CTG TGC ACC 591
 Cys Gly Leu Ala Asp Tyr Ala Asp Asp Gly Glu Lys Thr Leu Cys Thr
 155 160 165

5 AGC TGT GCT ATG TTT GAA GCC TGAGGTGGCC ACAGACAGCA CAAGATGTTC 642
 Ser Cys Ala Met Phe Glu Ala
 170 175

10 ACACTAAAGA GAGAGAAGGT GGCTTTTTAT ATGTTATGTT TTATACCCAG TAACAAGTGA 702
 ATAAACCTCT TTATATTTGC AAAAAAAAAA AAAAAAAAAA AAAAAAATTT CCGCGGCCGC 762
 AAGCTTAT 770

15 (2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 175 amino acids

(B) TYPE: amino acid

20 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

25

Met Pro Lys Arg Ser Cys Pro Phe Ala Asp Ala Ala Pro Leu Gln Leu
 1 5 10 15

30 Lys Val His Val Gly Leu Lys Glu Leu Ser His Gly Val Phe Ala Glu
 20 25 30

Arg Tyr Ser Arg Glu Val Phe Glu Arg Thr Lys Gln Leu Leu Phe Gln
 35 40 45

35 Gly Ala Arg Ala Tyr Arg Asp His Ile Ser Ser Glu Asp Cys Ser Val
 50 55 60

- 72 -

Asn His Leu Gln Glu Ser Leu Lys Ser Gly Val Val Gly Ala Pro Gln
 65 70 75 80

Pro Ala Arg Gly Gln Met Leu Ile Gly Pro Asp Gly Arg Leu Thr Arg
 5 85 90 95

Cys Gln Ala Gln Ala Ser Glu Gly Gly Leu Pro Arg Thr Ala Pro Ile
 100 105 110

10 Ala Cys Ser Ser Cys Met Arg Ser Val Asp Gly Lys Ala Val Cys Ser
 115 120 125

Gln Cys Glu Arg Ala Leu Cys Gly Gln Cys Val Tyr Thr Ser Trp Gly
 130 135 140

15 Cys Gly Ala Leu Ala Cys Val Leu Cys Gly Leu Ala Asp Tyr Ala Asp
 145 150 155 160

20 Asp Gly Glu Lys Thr Leu Cys Thr Ser Cys Ala Met Phe Glu Ala
 165 170 175

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 75 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Leu Gly Ala Gln Ala Tyr Leu Asp His Val Trp Asp Glu Gly Cys Ala
 1 5 10 15

35 Val Val His Leu Pro Glu Ser Pro Lys Pro Gly Pro Thr Gly Ala Pro
 20 25 30

- 73 -

Arg Ala Ala Arg Gly Gln Met Leu Ile Gly Pro Asp Gly Arg Leu Ile
35 40 45

5 Arg Ser Leu Gly Gln Ala Ser Glu Ala Asp Pro Ser Gly Val Ala Ser
50 55 60

Ile Ala Cys Ser Ser Cys Val Arg Ala Val Asp
65 70 75

10

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Cys Thr Leu Cys Gly Leu Val Asp Cys Ser Asp Met Tyr Glu Lys Val
1 5 10 15

25 Leu Cys Thr Ser Cys
20

(2) INFORMATION FOR SEQ ID NO:9:

30 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: protein

- 74 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Cys Ser Ser Cys Val Arg Ala Val Asp Gly Lys Ala Val Cys Gly Gln
 1 5 10 15
 Cys Glu Arg Ala Leu Cys Gly Gln Cys Val Arg Thr Cys Trp Gly Cys
 20 25 30

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 65 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Asp Pro Ser Gly Val Ala Ser Ile Ala Cys Ser Ser Cys Val Arg Ala
 1 5 10 15
 Val Asp Gly Lys Ala Val Cys Gly Gln Cys Glu Arg Ala Leu Cys Gly
 20 25 30
 Gln Cys Val Arg Thr Cys Trp Gly Cys Gly Ser Val Ala Cys Thr Leu
 35 40 45
 Cys Gly Leu Val Asp Cys Ser Asp Met Tyr Glu Lys Val Leu Cys Thr
 50 55 60

Ser

- 75 -

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Cys Thr Leu Cys Gly Leu Val Asp Cys Ser Asp Met Tyr Glu Lys Val
1 5 10 15
15 Leu Cys Thr Ser Cys
20

(2) INFORMATION FOR SEQ ID NO:12:

- 20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

30 Cys Ser Ser Cys Val Arg Ala Val Asp Gly Lys Ala Val Cys Gly Gln
1 5 10 15
Cys Glu Arg Ala Leu Cys Gly Gln Cys Val Arg Thr Cys Trp Gly Cys
20 25 30

- 76 -

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following

5 claims.

- 77 -

What is claimed is:

1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a *Siva* protein or a portion thereof.

5

2. The isolated nucleic acid molecule of claim 1, comprising a nucleotide sequence encoding *Siva-1* protein or a biologically active portion thereof.

3. The isolated nucleic acid molecule of claim 2, wherein the *Siva-1* protein comprises an amino acid sequence at least about 80% homologous to the entire amino acid sequence of SEQ ID NO:2

10

4. The isolated nucleic acid molecule of claim 2, wherein the portion of the *Siva-1* protein comprises one or more of the following domains and is capable of modulating apoptosis:

15

a) a death domain homology region which is at least about 50% homologous to the amino acid sequence of SEQ ID NO:7;

b) a zinc finger domain which is at least about 50% homologous to the amino acid sequence of SEQ ID NO:8; and

20

c) a B-Box like ring finger domain which is at least about 50% homologous to the amino acid sequence of SEQ ID NO:9.

5. The isolated nucleic acid molecule of claim 2, comprising the coding region of the nucleotide sequence of SEQ ID NO:1.

25

6. The isolated nucleic acid molecule of claim 1, comprising a nucleotide sequence encoding a *Siva-2* protein or a portion thereof.

7. The isolated nucleic acid molecule of claim 6, wherein the *Siva-2* protein comprises an amino acid sequence at least about 70% homologous to the entire amino acid sequence of SEQ ID NO:4.

30

8. The isolated nucleic acid molecule of claim 6, comprising the coding region of the nucleotide sequence of SEQ ID NO:3.

35

- 78 -

9. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a protein or portion thereof, wherein the protein or portion thereof comprises an amino acid sequence which is sufficiently homologous to an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 such that the protein or portion thereof maintains the ability to modulate apoptosis of a CD27-bearing cell.
10. An isolated nucleic acid molecule at least 15 nucleotides in length which hybridizes to a nucleic acid molecule encoding a *Siva* protein.
11. The isolated nucleic acid molecule of claim 10 which encodes human *Siva-1* or human *Siva-2*.
12. An isolated nucleic acid molecule encoding a *Siva* fusion protein.
13. An isolated nucleic acid molecule which is antisense to the nucleic acid molecule of claim 2 or 6.
14. A vector comprising a nucleotide sequence encoding *Siva*.
15. A host cell containing the vector of claim 14.
16. A method for producing *Siva* comprising culturing the host cell of claim 15 in a suitable medium until *Siva* is produced.
17. An isolated *Siva* protein or a portion thereof.
18. An isolated protein comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or a portion thereof.
19. A fusion protein comprising a *Siva* polypeptide operatively linked to a non-*Siva* polypeptide.
20. An antigenic peptide of *Siva* comprising at least 8 amino acid residues of the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:4.
21. An antibody that specifically binds *Siva*.

- 79 -

22. A method for detecting the presence of *Siva* in a biological sample comprising contacting a biological sample with an agent capable of detecting *Siva* protein or mRNA.

5 23. A kit for detecting the presence of *Siva* in a biological sample comprising a labeled or labelable agent capable of detecting *Siva* protein or mRNA in a biological sample.

10 24. A method for identifying a compound capable of treating a disorder characterized by aberrant *Siva* nucleic acid expression or *Siva* protein activity comprising assaying the ability of the compound or agent to modulate the expression of *Siva* nucleic acid or the activity of the *Siva* protein thereby identifying a compound capable of treating a disorder characterized by aberrant *Siva* nucleic acid expression or *Siva* protein activity.

15 25. A method for identifying a compound which binds to *Siva* protein comprising contacting the *Siva* protein with the compound under conditions which allow binding of the compound to the *Siva* protein to form a complex; and detecting the formation of a complex of the *Siva* protein and the compound in which the ability of the
20 compound to bind to the *Siva* protein is indicated by the presence of the compound in the complex.

25 26. A method for identifying a compound which inhibits the interaction of the *Siva* protein with a target molecule comprising contacting, in the presence of the compound, the *Siva* protein and the target molecule under conditions which allow binding of the target molecule to the *Siva* protein to form a complex; and detecting the formation of a complex of the *Siva* protein and the target molecule in which the ability of the compound to inhibit interaction between the *Siva* protein and the target molecule is indicated by a decrease in complex formation as compared to the amount of complex
30 formed in the absence of the compound.

1/4

-132 AGCCAAGCGTGGTGGCATGTGCCCTGTAATCCCAGCTACTCAGGAGGCTGAGGCATGAGAA
-72 TCTCTTGAACCCAGAGGTGTAGGTTGCAGTGAGCAGAGATTGTGCCACTGCACCTCCAGC
-12 CTGGCGACAGCATGAGCGGCCCGGGAGCTGCGTAGCTCCGGCCCCCGGCCCATGCCCC
H R R P G S C V A P G P A A M P
49 AAGCGGAGCTGCCCCCTTCGCGGACGTGGCCCCCGCTACAGCTCAAGGTCCGCGTGAGCCAG
K R S C P F A D V A P L Q L K V R V S Q
109 AGGAGTTGAGCCCGCGGTGTGCGCCGAGCGCTACTCGCAGGAGGTCTTCGAGAAGACC
R E L S R G V C A E R Y S Q E V F E K T
169 AAGCGACTCCTGTTCTCGGGGCCAGGCCCTACCTGGACCACGTGTGGGATGAAGGCTGT
K R L L F L S A Q A Y L D H V W D E G C
229 GCCGTCGTTCACTGCCAGAGTCCCCAAAGCCTGGCCCCCTACAGGGGCCCGAGGGCTGCA
A V V H L P E S P K P G P T G A P R A A
289 CGTGGCAGATGCTGATTGGACCAGACGGCCGCTGATCAGGAGCCTTGGGCAGGCCTCC
R G Q H L I G P D G R L I R S L G Q A S
349 GAAGTGACCCATCTGGGGTAGCGTCCATTGCCCTGTTCTCTCATGCGTCCGAGCCGTGGAT
K A D P S G V A S I A C S S C V R A V D

FIGURE 1A

RECTIFIED SHEET (RULE 91)
ISA / EP

2/4

409 GGGAAAGCGGTCTGCGGTCAAGTGTGAGCGAGCCCTGTGCGGCAGTGTGTGCGCACCTGC
G K A V C G Q C E R A L C G Q C V R T C

469 TGGGGTGC GGCTCCGTGGCCCTGTACCCCTGTGTGGCCCTCGTGGACTGCAGTGACATGTAC
W G C G S V A C T L C G L V D C S D H Y

529 GAGAAAGTGTGTGCACCAAGCTGTGCCATGTTTCGAGACCTGAGGCTGGCTCAAGCCGGCT
E K V L C T S C A H F L T

589 GCCTTCACCGGAGCCACGCCGTGCATGGCAGCCTTCCCTGGACGAGCGCTCGGTGTCA

649 GTGGGGTCGACGGGAGGGGTGCCCTTTTACATGTTCTATTTTGTATCCTAATGACAGAAATG

709 AATAAACCTCTTTATATTTCACAAAAAATAAAAAAATACTCGAG

FIGURE 1B

3/4

1/1
 31/11
 TTT GGC TCC GAG GCC AAG AAT TCG GCA CAG GGG CTC GGC GCG CGG CGC CGT GCG CGC TGC
 F G S E A K N S A R G L G A R R A A R C
 61/21
 91/31
 TGA AGG CTG TGT CTG GTA CCC GCT ACC ATG CCC AAG CGG AGC TGC CCG TTC GCA GAC GCA
 * R L C L V P A T M P K R S C P F A D A
 121/41
 151/51
 GCC CCG CTC CAA CTC AAA GTC CAC GTG GGC CTG AAA GAG CTG AGC CAC GGT GTG TTC GCC
 A P L Q L K V H V G L K E L S H G V F A
 181/61
 211/71
 GAG CGC TAC TCA CGC GAG CTG TTC GAA AGA ACC AAG CAG CTC CTT TTC CAA GGG GCT CGG
 E R Y S R E V F E R T K Q L L F Q G A R
 241/81
 271/91
 GCC TAT AGA GAT CAC ATA TCG ACG GAA GAT TGT TCC GTG AAC CAC CTG CAG GAG TCA CTG
 A Y R D H I S S E D C S V N H L Q E S L
 301/101
 331/111
 AAG TCT GGT GTG GTA GGA GCC CCT CAA CCT GCG AGG GGA CAG ATG TTG ATT GGA CCT GAT
 K S G V V G A P Q P A R G Q M L I G P D
 361/121
 391/131
 GGC CGA CTG ACA CGG TGC CAA GCT CAG GCC TCA GAA GGT GGC CTT CCC AGG ACA GCG CCC
 G R L T R C Q A Q A S E G G L P R T A P
 421/141
 451/151
 ATC GCT TGT TCA TCG TGC ATG AGA TCT GTG GAT GGG AAG GCG GTC TGC AGC CAG TGC GAG
 I A C S S C M R S V D G K A V C S Q C E

FIGURE 2A

RECTIFIED SHEET (RULE 91)
 ISA / EP

481/161 511/171
 CGG GCC CTG TGT GGG CAG TGT GTA TAC ACC AGC TGG GGC TGC GGT GCT TTG GCC TGT GTG
 R A L C G Q C V Y T S W G C G A L A C V
 541/181 571/191
 CTG TGT GGC CTT GCA GAC TAT GCC GAC GAT GGT GAG AAG ACA CTG TGC ACC AGC TGT GCT
 L C G L A D Y A D D G E K T L C T S C A
 601/201 631/211
 ATG TTT GAA GCC TGA GGT GGC CAC AGA CAG CAC AAG ATG TTC ACA CTA AAG AGA GAG AAG
 M F E A * G G H R Q H K M F T L K R E K
 661/221 691/231
 GTG GCT TTT TAT ATG TTA TGT TTT ATA CCC AGT AAC AAG TGA ATA AAC CTC TTT ATA TTT
 V A F Y M L C F I P S N K * I N L F I F
 711/241 751/251
 GCA AAA AAA AAA AAA AAA AAA AAA AAT TTC CGC GGC CGC AAG CTT AT
 A K K K K K K K K N F R G R K L

4/4

FIGURE 2B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/10862

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C12N15/62 C07K14/47 C07K16/18 A61K38/17
A01K67/027 C12Q1/68 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 05691 A (IMMUNEX CORP) 17 March 1994 see claims 1-19 ---	1-26
A	BOWMAN MR ET AL: "The cloning of CD70 and its identification as the ligand for CD27." J IMMUNOL, FEB 15 1994, 152 (4) P1756-61, XP002016676 UNITED STATES see abstract --- -/--	1-26

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

14 September 1998

Date of mailing of the international search report

25/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gurdjian, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/10862

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>PRASAD KV ET AL: "CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein."</p> <p>PROC NATL ACAD SCI U S A, JUN 10 1997, 94 (12) P6346-51, XP002077447</p> <p>UNITED STATES</p> <p>see the whole document</p> <p>-----</p>	1-21

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/10862

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9405691 A	17-03-1994	US 5573924 A	12-11-1996
		AU 5099293 A	29-03-1994
		CA 2144056 A	17-03-1994
		EP 0662077 A	12-07-1995
		JP 8500976 T	06-02-1996
<hr/>			